Frontiers in Health Informatics
ISSN-Online: 2676-7104
www.healthinformaticsjournal.com
2024;Vol. 13:Issue 7
OpenAccess

Computer Aided Drug Discovery Driven Approaches for Discovery of Antimicrobial Agents

Manoj. G. Damale, Rashmi. S. Chouthe, Harshali. A. Takale, Aparna. S. Kumare, Aishwarya. S. Bhadke, Mayuri. S. Chape, Komal. V. Gadhe, Santosh. D. Shelke
Department of Pharmaceutical Chemistry,
Srinath College of Pharmacy,
Chh. Sambhajinagar-431001(MS),India.
Corresponding author: Manoj. G. Damale, pharmalink1985@gmail.com

Cite this paper as: Manoj. G. Damale, Rashmi. S. Chouthe, Harshali. A. Takale, Aparna. S. Kumare, Aishwarya. S. Bhadke, Mayuri. S. Chape, Komal. V. Gadhe, Santosh. D. Shelke (2024) Computer Aided Drug Discovery Driven Approaches for Discovery of Antimicrobial Agents. *Frontiers in Health Informatics*, *Vol.13, No.7 (920-972*

Abstract:
Computer-Aided Drug Design/Discovery (CADD) is a powerful and evolving field that employs computational techniques to facilitate the discovery and optimization of new therapeutic agents. The global problem of antibiotic resistance has been addressed by recent developments in Computer-Aided Drug Design (CADD), which have greatly improved the development of antimicrobial agents. Using computational techniques such as molecular docking, quantitative structure-activity relationship (QSAR) modeling, virtual screening, quantum computing and molecular dynamics simulations, CADD provides novel approaches for the logical design of novel antimicrobial compounds. These methods greatly impact on the time and expense associated with conventional drug discovery procedures by enabling the identification of possible drug candidates, the optimization of their pharmacokinetic characteristics, and the prediction of drug-target interactions. There are still a number of restrictions on using CADD for antimicrobial drug discovery, even with these developments. Additionally, problems with bioavailability, toxicity, and off-target effects cause many antimicrobial agents to fall short of in silico predictions in terms of clinical efficacy. With the combination of artificial intelligence (AI) and machine learning (ML) improving predictive accuracy and efficiency, the future of CADD in antimicrobial development looks bright. AI/ML models can offer fresh perspectives on the mechanisms underlying microbial resistance and further optimize drug design. Furthermore, the creation of hybrid computational methods that combine experimental data and CADD may accelerate the discovery of new antimicrobial agents. The future of developing antimicrobial drugs will be shaped by the computational resources through ongoing evolution.

Keywords: Computer-Aided Drug Design/Discovery, Molecular docking, Antimicrobial agent, Artificial intelligence, Quantum computing, Machine learning.

Introduction to CADD:

Computer-Aided Drug Design (CADD) is the process of discovering, designing, and developing new pharmaceutical compounds with the help of simulations and computational methods. Using the power of computational tools to predict and optimize the interactions between drug molecules and biological targets speeds up the drug development process.

Because it enables researchers to predict drug activity, lower experimental costs, and expedite the development of effective drugs, CADD has emerged as a crucial tool in the fields of medicinal chemistry and pharmaceutical research. To clarify and expedite the drug discovery process and create new medications (such as antibiotics) for both known and unknown targets, CADD can be used in conjunction with wet laboratory techniques. CADD streamlines the medication design procedure by cutting down on time and cost[1–3]

Antimicrobial resistance (AMR) is an escalating worldwide issue that presents a significant risk to human health and the sustainability of healthcare systems. Antimicrobial resistance (AMR) occurs when bacteria, fungi, parasites, and viruses can survive and multiply despite the presence of previously effective drugs[4]. There are several mechanisms involved in the development of microbial resistance. These include changes in cell membrane permeability; efflux pump formation, drug target modification, and antibiotic degradation due to enzyme breakdown or alteration of the enzyme scaffold[5–8].



Fig-1: Overview of CADD

Strategies in CAAD for antimicrobial agents:-



Fig-2: Types of CADD

Structure Based Drug Design

SBDD is a technique that uses knowledge of the drug target's structure to develop a medication that can block it. This approach requires knowledge of the receptor's structure. Methods like as X-ray crystallography or NMR are often used to determine the receptor's structure. In the lack of the structural data of the protein target, computer techniques such as threading or homology modeling can be used to predict it. A method for modeling proteins that lack structurally similar proteins is called threading. The process of threading involves comparing the amino acid sequence to structures in a database of recognized protein shapes. These shapes are then used to construct the protein structure. The technique of homology modeling relies on a distinct relationship between the structure of a known protein and the sequence of the target protein[9,10].Finding a similar protein with a known 3D structure to use as a template, aligning the target and template proteins' sequences, building a model for the target based on the alignment and the template's 3D structure, and then refining and verifying the model are the steps involved in homology modeling of proteins[11,12].When crystal structures are unavailable, homology modeling has emerged as the primary technique for obtaining a 3D model of the target[13].

Molecular docking:-

Molecular docking is a computer-based method for examining the interactions between a target and a small molecule, or ligand. It operates by inserting the tiny molecule into the target's active site using specialized software, searching for the ideal fit and location. Using a scoring system, these programs examine the molecule's various shapes and locations to forecast how strongly it will bind in each. This aids in the identification of crucial substances that firmly attach to a target protein or other significant molecules implicated in cancer[14]. By reducing the number of compounds that must be created and tested in the lab or on living things, it increases the speed at which cancer drugs are discovered[15].n cancer drug research, molecular docking is done using a variety of computer software tools. In drug discovery, Glide is a popular docking program.[16, 17]. These computer programs can identify novel compounds that bind to cancer-related proteins with high strength, accelerating drug discovery and improving cancer treatments. Because every program has pros and cons, the decision is based on the objectives of the research as well as the resources that are available[18].

Table- 1: Common Molecular docking tools for structure prediction and how they interact with a target.

Sr. No.	Tools	Method	Links
1.	Pyrex	Pyrex is used for the virtual screening of molecular libraries to identify potential drug candidates.	https://pyrx.sourceforge.io/downloads[19]
2.	BIOVIA Discovery Studio Visualizer	BIOVIA Discovery Studio Visualizer is used for viewing and analyzing molecular structures and simulations.	https://www.3ds.com/products/biovia/discovery-studio/visualization[20]
3.	Pymol	PyMOL is used for visualizing and analyzing 3D molecular structures.	https://www.pymol.org/[21]
4.	Auto Dock Vina	Auto Dock Vina is used for performing molecular docking to predict how small molecules bind to a target protein.	https://vina.scripps.edu/downloads/[22]
5.	Haddock	HADDOCK is used for predicting protein-protein and protein-ligand interactions through computational docking.	https://rascar.science.uu.nl/haddock2.4/[23]
6.	Auto Dock	Auto Dock is used for molecular docking to predict how small molecules interact with a target protein.	https://autodock.scripps.edu/[24]

Structure-based virtual screening [SBVS]:

In order to predict how two molecules can bind together to form a stable complex, SBVS, also known as target-based VS (TBVS), is used. Techniques that examine the molecular target's three-dimensional structure are part of the SBVS method. When the molecular target's three-dimensional structure has been established through experimentation, SBVS is the recommended method. Based on the strength of their bond, SBVS seeks to forecast the likelihood that candidate molecules will bind to the target protein[25,26]. Because it is less expensive to compute and produces good results, molecular docking is the most widely used SBVS method[27,28]. Despite the aforementioned limitations, a large number of studies have recently been developed that use SBVS. This demonstrates that despite certain drawbacks, SBVS is still frequently employed in the creation of new medications due to its time and cost savings[29].



Fig-3: Structure-based virtual screening work-flow

De Novo Drug Design

Computational de novo design is a technique that uses a fragment-based approach to potentially create biologically active compounds. In addition to a set of predetermined chemical building blocks and fundamental principles for joining them, this entails using the biological target's structure as a guide[30]. A de novo design program must address three primary questions: how to assemble the candidate compounds, how to assess their possible quality, and how to effectively search through potential options. The primary advantage of this technique is that it makes it possible to investigate a variety of virtual structures without having to actually produce a significant number of compounds.

Common homology modeling tools for structure prediction and how they predict structures.

Table-2: De Novo Modeling Tools

Sr. No.	Tools	Method	Links
1.	LUDI	A tool that uses fragment-based techniques to create new molecules by joining small chemical pieces in a way that matches the target protein's binding site.	-
2.	SPROUT	A program made to create new molecular structures by putting together small pieces or frameworks, with the aim of making drug-like molecules.	https://www.keymodule.co.uk/sprout-classic/[31]
3.	LigBuilder	A tool for de novo drug design that uses a step-by-step method to create molecules by joining fragments that fit nicely into the target binding site.	https://www.frontiersin.org/journals/chemistry/articl 9/fchem.2020.00142/full#:~:text=De%20novo%20D 0Approach,structures%20for%20design%20new%2 nds[32]
4.	DeNovo Designer (Schrödinger)	A platform that creates new drug candidates based on the structure of a target protein and uses methods like fragment-based design or changing the molecular structure.	https://www.schrodinger.com/platform/products/de-r design-workflow/[33]
5.	Rosetta	A computer tool used to predict and design protein structures, which can also be used to create small molecules in de novo drug design.	https://rosettacommons.org/software/[34]
6.	MOE (Molecular Operating Environment)	Although MOE is a versatile tool, it has special features for de novo design that help create new molecules by combining small building blocks.	https://www.chemcomp.com/Products.htm[35]
7.	GASP (Generative Active Scaffold Pathways)	A tool that creates new molecules by finding the best ways to change an existing structure to match known biological targets.	-

Ligand based drug design:-

Ligand-based drug design is an indirect methodology aimed at advancing the creation of pharmacologically active drugs via the examination of molecules that engage with the biological target of interest[36]. Conversely, structural-based drug design techniques use the three-dimensional structure of the target molecule to find or enhance therapeutic candidates[37–39].

The first step in any drug design process is the identification of an appropriate target molecule linked to a disease. A principal protein within a biochemical pathway linked to the illness state

functions as a prospective therapeutic target[40–42]. Contingent upon the characteristics of the illness condition, Molecules, known as lead compounds, are found or engineered to block or enhance the relevant metabolic process[43–46]. The subsequent phase in the pharmacological discovery process is to enhance the lead compounds to optimize their interaction with the target molecule. CADD is capable of play an essential part in directing the lead optimization process. CADD techniques may be used for both ligand-based and structure-based drug design. Ligand-based drug design techniques are advantageous when an experimental 3D structure is unavailable[47–50]. in the absence of an experimental structure, the known ligand molecules that interact with the therapeutic target are analyzed to elucidate the structural and physicochemical features of the ligands that correspond with their intended pharmacological action[51]. In addition to recognized ligand molecules, ligand-based methodologies may include natural compounds or substrate analogues that engage with the target molecule, producing the intended pharmacological action[52–54]. Conversely, when a 3D structure of the drug target is available, structure-based techniques, like molecular docking or in silico chemical modification, are often used for lead optimization[55,56]. This method utilizes the accessibility of the target 3D structure to ascertain the characteristics of the target-ligand interaction and the structural prerequisites of the ligand to enhance the relationship.

I. Quantitative Structure-Activity Relationship (QSAR):

Pharmacophore modeling and the QSAR methodology are the main methodologies used in ligand-based drug design. The correlation between the chemical structures of diverse chemicals and specific chemical or biological effects is assessed by the computational method termed QSAR. The fundamental principle of the QSAR approach is that compounds with analogous structures or physicochemical properties will exhibit similar behavior. Initially, a compilation of chemical entities or lead compounds demonstrating the requisite biological activity of interest is identified[57,58]. The biological activity of active substances is quantitatively correlated with their physical properties. The active compounds are then optimized to enhance the relevant biological activity using the created QSAR model. The expected activity of the substances is then evaluated experimentally. Consequently, the QSAR approach may serve as a framework for identifying chemical changes that enhance activity.

The general methodology of QSAR is built upon a series of consecutive steps:

I. Determine which ligands exhibit the desired biological activity as measured experimentally. Although a congeneric series is ideal, these ligands should also have sufficient chemical diversity to exhibit a wide range of activity.
II. Determine the molecular descriptors linked to the different structural and physico-chemical characteristics of the molecules being studied.
III. Find relationships that can account for the variation in activity in the data set between biological activity and molecular descriptors. The proper biological effect is tested for a set of compounds based on the study's objectives, and the results are used as the basis for QSAR modeling.

Molecular mechanics or quantum techniques are used to reduce the energy of the molecules after they have been selected for the study and simulated on a computer. In order to explain

the chemical characteristics required for the molecules' biological activity, significant molecular descriptors are then developed for the collection of molecules[59–61]. These characteristics may be structural or associated with chemical and physical attributes. The goal is to give each molecule a molecular "fingerprint" that is connected to its activity. These descriptors can be produced using knowledge-based, molecular mechanics-based, or quantum chemistry-based tools, depending on the QSAR technique. After that, a mathematical relationship is developed using the molecular descriptors to explain the variations in the molecules' biological activity. To guarantee the models' statistical significance, dependability, and outcome-productiveness, they undergo a series of tests in the last stage. QSAR is now a crucial step in the drug development process since techniques for completing these steps have advanced over time. The kinds of molecular descriptors that are employed and how they relate to the activity have been the primary areas of advancement in QSAR techniques. The remainder of this review will provide a summary of the primary QSAR techniques, emphasizing their main distinctions, before going into great detail about the CSP-SAR technique that was created in our labs.

Statistical Tools for Model Development and Validation

Choosing the appropriate molecular descriptors and being able to establish the proper mathematical relationship between the descriptors and the biological activity under study are key components of any successful QSAR model. It has been obvious since the inception of QSAR that the most crucial aspect of the technique is defining molecular descriptors[62,63]. Many molecular descriptors that can be utilized in QSAR techniques can now be created thanks to recent software advancements[64,65].

CoMFA:

CoMFA stands for Comparative Molecular Field Analysis[66]. CoMFA is a well-liked 3D QSAR technique that correlates a molecule's biological activity with its 3D shape, steric, and electrostatic characteristics. Potential energy values are computed at each location on a three-dimensional grid of molecules. The biological activity is then contrasted with these values. The CoMFA model is constructed using techniques like PCA and PLS, and its dependability is evaluated. The degree of alignment of the bioactive shapes determines the model's success[67–69].

CoMSIA:

CoMSIA denotes Comparative Molecular Similarity Indices[70]. CoMSIA is a three-dimensional quantitative structure-activity relationship approach that is equivalent to CoMFA. In contrast to CoMFA, CoMSIA's molecular field incorporates steric and electrostatic variables, in addition to hydrophobic, hydrogen-bond donor, and acceptor components. To ascertain similarity scores instead of interaction energies, CoMSIA evaluates each ligand molecule against a standard probe with identical charge, hydrophobicity, and hydrogen bond attributes, with a radius of 1Å. The steric, electrostatic, and hydrophobic elements of the energy function are characterized by CoMSIA via a bell-shaped Gaussian function. This approach does not need an arbitrary cutoff number for energy estimates, unlike CoMFA. The similarity scores of CoMSIA's molecular fields assist in characterizing the ligand-protein interaction[71,72].

Ligand-Based Virtual Screening (LBVS):-

LBVS uses virtual libraries of compounds to identify other molecules with similar structures

based on molecules with known biological effects. This approach disregards the target molecule's structure. Its premise is that molecules with comparable shapes might have comparable biological effects. Therefore, LBVS seeks to identify compounds with comparable molecular structures or essential functional components, increasing the possibility of discovering compounds with biological activity. Comparing the characteristics of known molecules—derived from reference compounds—with those of molecules in databases is how LBVS is carried out. Measures of similarity are used to accomplish this. Although there are various ways to determine how similar two sets of molecular features are, one popular method is to use the Tan moto coefficient[73].



Fig-4: Virtual screening

Fragment based drug design:

Despite significant scientific and technological advancements aimed at enhancing drug discovery in the pharmaceutical industry, more investment has not resulted in a notable increase in the quantity of new drugs that are brought to market. More creative technologies and approaches are required to address these issues. Using tiny, weakly binding fragments as the foundation for incremental advancements is one promising strategy[74].

This approach, called Fragment-Based Drug Discovery (FBDD), has its roots in William Jencks's 1981 research.

I. The concept is that the sum of the energies from each fragment's binding to the target is the total binding energy of a molecule with its target. For a long time, though, this idea did not receive much attention. Finding appropriate fragments that bind to the appropriate regions of the target and

II. Enhancing these fragments by joining, combining, or cultivating them into drug-like molecules without altering their initial binding patterns are the two primary challenges. Abbott scientists were the first to successfully use FBDD in drug discovery. Since then, FBDD has grown in importance alongside combinatorial chemistry and conventional high-throughput screening (HTS). It combines the benefits of structure-based drug

design and random screening. Large collections of drug-like molecules are tested using traditional HTS techniques, which frequently yield a large number of promising candidates, but only a small percentage reach the market. Problems like poor drug properties and a lack of chemical diversity (e.g. G. toxicity, excretion, metabolism, distribution, and absorption) frequently prevent additional growth. On the other hand, FBDD assists in locating tiny active fragments that can enter difficult-to-reach areas of the target. Once these interactions are well understood, they can aid in the development of stronger and more efficient medications. Higher hit rates, improved binding efficiency, and more efficient optimization are provided by FBDD in contrast to conventional HTS or virtual screening. Practically speaking, there are more options for structural modifications and a wider range of chemical possibilities when the fragment is smaller. The creation of fragment libraries is the main topic of this review, along with the benefits and drawbacks of various fragment-based screening techniques for finding valuable fragments. We also highlight how well-known fragments from previously reported molecules can be broken down and rebuilt[75].

Target Selection and Preparation:

Target Selection:

I. Identify a Therapeutic Target: Focus on proteins or biomolecules that are essential in the disease you're aiming to treat. This could be enzymes, receptors, or critical proteins in signaling pathways[76].

II. Structural Characterization: Obtain detailed information about the 3D structure of the target protein using techniques such as X-ray crystallography, NMR spectroscopy, or computational modelling. This information is crucial for understanding potential binding sites [77].

III. Evaluate Drug ability: Assess whether the target's binding sites are suitable for interaction with small drug-like molecules. Drug ability focuses on the potential to achieve effective and specific binding, which is essential for developing a successful drug[78].

Target Preparation:

1) Establish a Fragment Library:

Create or obtain a varied collection of tiny chemical fragments. Though typically having a molecular weight of less than 300 Da, these fragments have a variety of chemical characteristics that allow for a wide range of possible interactions. Check for Interactions: Use a variety of biophysical methods, such as High Throughput Screening (HTS), Nuclear Magnetic Resonance (NMR), or Surface Plasmon Resonance (SPR), to compare the fragment library to the target protein. This stage finds the fragments that attach to the active site of the target. Binding Validation and Optimization: To verify the fragments' interaction with the target, validate them with more binding studies. Enhancing the fragments' binding affinity and selectivity through further optimization is necessary to turn them into lead compounds for drug development[79].

2) Fragment Library Design and Selection:



Fig-5-: Fragment Library Design

Recent research has examined the qualities of a good fragment library[80]. The fragments' physical and chemical characteristics, their ability to dissolve in water and meet quality standards, the diversity of molecules in the library, their ease of modification for future research, the chemical features that should be avoided, their resemblance to well-known oral medications and natural products, and their inclusion of common medicinal chemistry structures are the main considerations. There are some things that all fragment libraries agree on, even though they may have slightly different ideas about what constitutes a good fragment. To put it simply, a fragment should pass complexity tests (based on things like hydrogen bond donors, acceptors, or rotatable bonds, or using a complexity fingerprint), weigh no more than 300 Da (as recommended by Astex Therapeutics in their "rule of three"), and dissolve well in water for screening purposes of practicality[81].

3) Fragment Screening:

Creating and testing a large library in a bioassay is more difficult than creating and testing a small library of fragments in an academic setting using biophysical techniques like protein-ligand NMR, surface Plasmon resonance (SPR), or even X-ray crystallography. Actually, in the early 1990s, the University of Groningen conducted some of the earliest research on the use of X-ray crystallography for fragment screening. Top academic labs frequently have top-notch NMR equipment and other biophysical techniques, and numerous recent studies by academic groups have applied fragment-based drug discovery (FBDD) methods to new targets[82–88].

4. Hit Identification and Validation:

The biochemical and biophysical techniques used to identify fragment hits have been reviewed elsewhere and will not be covered here[89]. Several tests are frequently used to measure binding and activity, and NMR spectroscopy and surface Plasmon resonance (SPR) are two popular screening techniques[90]. Nonetheless, a number of studies have noted that various screening techniques can produce disparate outcomes for the same target [91]. These variations could result

from different test requirements, different hit definition criteria, or different method sensitivities. Binding assays may frequently be functioning near the boundaries of what is currently detectable[92].

5. Fragment Optimization:

I) NMR-Based Screening:

A significant discovery technique is the SAR by NMR method, which use NMR to identify small compounds that bind to a protein target. A fragment library is first analyzed to discover compounds that bind to a 15N-labeled protein. 2D HSQC spectra show changes in chemical shifts at the binding site upon drug binding [93]. Alongside structural data, these alterations assist in identifying the exact location on the protein where the chemical attaches. Compounds that interact with neighboring sites are then selected and optimized. These chemicals are used to augment individual protein fragments or to concatenate fragments that are intimately associated by using the protein's three-dimensional conformations. Functional experiments are used to ascertain if the modified fragments can inhibit the protein [94,95].

ii) Methods Based on Mass Spectrometry:

Two main methodologies have discerned weak binding ligands by mass spectrometry. Ibis Therapeutics, a subsidiary of Isis, developed a technique using electrospray ionization mass spectrometry (ESIMS) to detect weakly binding RNA fragments. They successfully investigated low-affinity complexes (in the mill molar range) between RNA and small molecules by optimizing the ionization and desolvation processes. They could determine the number of molecules involved in the interaction and the binding strength directly from the mass and amount of these complexes[96–98].

iii) Methods Based on Crystallography:

X-ray crystallography can offer the most comprehensive understanding of how fragments attach to a target. Similar to NMR, crystallography enables fragment optimization in addition to fragment detection. Early on, the slowness of crystallography as a screening method was criticized. However, the speed and efficiency of solving crystal structures have increased due to advancements in robotics, X-ray technology, and computer processing power. This method is now widely used in labs to support in the discovery of small-molecule inhibitors. The worry that tiny, weakly binding fragments might not give enough signal for a clear electron density in the solvent molecules could bind to particular protein surface sites was addressed by Ringer and associates[99,100].

iv) Lead Compound Development:

The fragment growing process starts as soon as fragments with high binding affinities are found. In order to improve interactions with the binding site and boost potency and selectivity without substantially changing the fragment's core structure, chemical groups are added to the fragment. It is occasionally possible to connect two or more fragments that bind to distinct areas of the target's binding site[101].This is accomplished by creating a single, larger molecule that preserves the binding properties of the individual fragments by designing a chemical linker to join them. It is frequently possible to combine fragments into a single, more complex molecule when they bind closely together within the same area of the binding site. This combined piece takes [102].

Pharmacophore Modeling:

To create new molecules, identify the key characteristics needed for biological activity. Several essential characteristics that are required for compounds to bind to a particular protein are identified by pharmacophore models. By looking for common characteristics among known active compounds, these models can be made. They can then be compared to vast collections of compounds to identify those that share those characteristics and may bind to the target protein. [103].

Table- 3: pharmacophore modeling tools

Sr. No.	Tools	Method	Links
1.	Ligand Scout	Ligand Scout is a program designed for creating pharmacophore models and virtual screening. It builds pharmacophore models from the 3D shapes of ligands and lets users study how ligands interact with their biological targets.	https://ligandscout.software.informer.com/[104]
2.	MOE (Molecular Operating Environment)	MOE provides a complete set of tools for computational chemistry, with special features for pharmacophore modeling. It supports both ligand-	https://www.chemcomp.com/Products.htm[105]

		based and receptor-based pharmacophore creation.	
3.	PHASE (Schrödinger)	PHASE is a tool in the Schrödinger software package made for both ligand-based and structure-based pharmacophore modeling. It helps you create pharmacophore models from small molecule information and carry out virtual screening.	https://www.schrodinger.com/platform/products/phase/[106]
4.	Discovery Studio (BIOVIA)	Discovery Studio offers a range of tools for molecular modeling, with a special focus on pharmacophore modeling. The software provides both ligand-based and receptor-based methods for making	https://www.3ds.com/products/biovia/discovery-studio/visualization[107]

		pharmacophore models.	
5.	PharmMapper	PharmMapper is an online tool that uses a ligand-based approach to generate pharmacophore models and map them to potential protein targets. It is primarily used for target identification and drug repurposing.	https://www.lilab-ecust.cn/pharmmapper/[108]
6.	Pharmacophore Fingerprints (Open Babel)	Open Babel is a free, open-source chemical tool that helps create pharmacophore fingerprints, which are helpful for structure-based virtual screening and searching ligand databases.	https://sourceforge.net/projects/openbabel/[109]



Fig-6: pharmacophore modeling

Limitations of CADD for antimicrobial Drug discovery:

Biological systems are intricate and governed by several key factors. Because of this, there are certain limitations and the complete biological system cannot be replicated and simulated on a computer using state-of-the-art technology. One of the most important problems with drug discovery that still exists is target flexibility[110]. The majority of molecular docking systems give the ligand a great deal of flexibility while either fixing the protein or only slightly allowing the residues close to the active site to move. Giving the protein complete molecular flexibility is challenging because it adds to the computation's temporal and spatial complexity. Nonetheless, attempts are being made to incorporate as many attributes as feasible. Conformational changes give receptor and target molecules a great deal of flexibility in solution[111].Therefore, developing an inhibitor based only on identifying a specific, hard structure might result in an inaccurate outcome. The ligand has considerable versatility using docking approaches; nevertheless, the residues near protein binding sites exhibit little flexibility[112]. Computer-aided drug design (CADD) is a critical endeavor owing to the inherent complexity of biological systems and the constraints of computational methods[113].Computer-aided drug design (CADD) offers significant advantages and holds considerable promise for advancing drug development. A significant obstacle in this area is the lack of skilled professionals in machine learning (ML) and artificial intelligence (AI) methodologies. The absence of such knowledge hinders CADD processes from properly integrating and optimizing AI/ML[114]. Organizations such as in-silico Medicine are leading initiatives to bridge this gap by cultivating a proficient workforce capable of using modern computational techniques for drug development. By overcoming these restrictions, enhanced methodologies may be established, facilitating more efficient drug discovery procedures[115].

The accuracy of predictive models:

Predictive model accuracy is one of the primary issues with computer-aided drug design (CADD), which is hampered by the computational limitations and the intrinsic complexity of biological systems. While CADD's predictive models are helpful resources, their accuracy can be significantly increased by combining various strategies and fixing the drawbacks of each one. Improving molecular simulations, using hybrid and ensemble models, and continuously improving scoring algorithms are essential for predicting the binding affinity between compounds and their targets in drug discovery. These improvements will be necessary for the advancement of CADD and the development of more potent therapeutic drugs[116]. The

possibility of false positives and negatives must be actively decreased in order to ensure their accuracy. This means adding numerous chemical descriptors, continuously validating against experimental data, and carefully calibrating the scoring criteria.

Data Quality and Quantity:

The accuracy of predictions made by CADD tools is contingent upon the data provided to them. Predictions are likely to be erroneous if the foundational data is insufficient or of poor quality. The absence of meticulously selected, high-quality datasets, particularly in the realm of pharmacological machine learning[117]. Outliers may be mitigated, and standardized data formats can improve molecular interaction datasets by reducing mistakes and increasing the accuracy of computer models. Additionally, employing tried-and-true experimental methods like endpoint measurements and consistent assay conditions improves the quality of the data in CADD and produces solid and trustworthy results.

Over-reliance on Computational Predictions:

CADD is an effective tool, but if its predictions are relied upon too much without further experimental confirmation, it may result in misdirected efforts. Even though CADD is a useful tool, concentrating too much on its predictions without additional experimental verification could lead to misdirected efforts. Successful drug discovery requires striking a balance between computational predictions and experimental evidence[118]. Effective drug discovery requires a balance between experimental data and computational predictions.

Time and Computational Cost:

Molecular dynamics simulations and machine learning models are two examples of sophisticated CADD (Computer-Aided Drug Design) approaches that can be very resource-intensive. For these simulations to model and simulate complex chemical systems over extended periods of time, massive computer power is usually needed, and the infrastructure needed can be expensive.

The key challenges include:

I. High computational costs: For example, molecular dynamics simulations need millions or billions of iterations to calculate the interactions between atoms and molecules. This may necessitate clusters of high-performance computing (HPC) equipment or cloud computing resources, which can soon result in substantial operational expenses.

II. Data Storage and Management: Storing huge datasets created during simulations or machine learning processes (e.g., protein-ligand binding affinities, energy states, and trajectory data) is both logistically and financially challenging. Proper administration and analysis of that data need efficient storage options, which frequently incur additional expenditures.

III. Time constraints: Depending on the complexity and scope of the study, some simulations might take weeks, months, or even years to complete. This raises the total time commitment and the possibility of delays in research results.

IV. Specialized Expertise: Researchers who are skilled in these cutting-edge approaches may need to pay more for further training or employment because, in addition to computational resources, specialized knowledge in their application is essential.

To address these problems, some research groups use cloud-based platforms or computing resources provided by university partnerships, or they optimize their models to reduce

computational load while maintaining accuracy. Furthermore, there is an increasing tendency towards using parallel processing and more efficient methods to reduce computing expenses. Some organizations also charge a fee for access to cutting-edge resources, allowing smaller research groups to use modern tools without incurring full infrastructure costs [119].

Molecular flexibility:

In computer-aided drug design (CADD), molecular flexibility is one of the most challenging aspects, particularly when using methods like molecular docking. Because biological systems are fundamentally dynamic, with interactions dictated by the movement and form-changing of molecules, flexibility in therapeutic compounds and target proteins is crucial. When illustrating molecular flexibility, the following are some of the main obstacles and factors to take into account.

1. Conformational Flexibility of Ligands:

Ligand: Drug candidates (ligands) can adopt various conformations, each with a unique binding affinity to the target protein. In molecular docking, attempting to account for all possible ligand conformations can result in an explosion in computing complexity.

Conformational Searching: Methods such as stiff docking (which assumes a fixed ligand conformation) are quick but frequently incorrect since they overlook the ligand's flexibility. Flexibility can be added through thorough conformational searches or utilizing molecular dynamics (MD) simulations, but both methods can be computationally expensive.

Rotatable Bonds: Ligands may have numerous rotatable bonds, complicating the search for the optimal docking conformation. Advanced sampling approaches, such as Monte Carlo simulations or Genetic Algorithms, can be useful, but they incur significant processing costs.

2. Protein Flexibility:

Induced Fit: When proteins bind to ligands, they change conformation. This means that the protein's structure may alter to accommodate the ligand, but these changes are difficult to anticipate and require simulations to account for the protein's dynamic nature. Traditional docking treats proteins as stiff, which restricts precision.

Flexible Receptor Docking: Some modern docking techniques provide flexible receptor docking, which allows the protein structure to move somewhat. However, precisely forecasting these movements and the consequent binding modes necessitates significant processing power. This is especially problematic for big proteins or systems with multiple degrees of freedom.

3. Complex Interactions:

- Water Molecules and Solvent Effects:

Water molecules and solvent interactions significantly impact ligand binding and molecular flexibility. Water molecules can occupy binding pockets and alter the ligand's conformation. Solvent modelling (e.g., implicit or explicit solvent models) increases the complexity of flexibility representation.

- Side-Chain Movements:

The flexibility of protein side chains can have a substantial impact on docking. Side chains can alter in response to ligand interaction, and if not adequately modelled, this can result in inaccurate predictions of binding affinities. Water molecules and solvent interactions play an important role in ligand binding and molecular flexibility. Water molecules can occupy binding pockets and alter the ligand's conformation. Solvent modelling (implicit or explicit solvent

models)

4. **Sampling and Scoring:**

Sampling: Efficiently sampling all possible conformations of both ligands and proteins is critical to determining the best binding mode. However, thorough conformational sampling is computationally impractical. Methods like as molecular dynamics simulations or Monte Carlo sampling are frequently employed to investigate the conformational space, although they are time-consuming.

Scoring Functions: The purpose of molecular docking scoring functions is to forecast the ligand and protein binding affinities. These functions, however, frequently depend on approximations and might not take into consideration all of the variables influencing flexibility, especially the induced fit and solvation effects. Studies.

5. Computational Cost:

- Efficiency vs. Accuracy:

To accurately represent molecular flexibility, more complex computational methods are required, such as MD simulations or advanced docking algorithms. These methods are frequently computationally expensive and time-consuming, particularly when dealing with large-scale systems (such as protein-protein interactions or complex ligands).

- Large Systems:

Docking big ligands or proteins adds a significant computational cost, especially if several conformations of both the ligand and protein must be examined [120].

Interpretability of AI Models: In fields like drug discovery and CADD, where comprehending the rationale behind a model's predictions can be just as crucial as the predictions themselves, the interpretability of AI and machine learning models is a crucial subject. When artificial intelligence models—especially deep learning or other extremely complex models—are viewed as "black boxes," it is challenging for researchers to completely trust their predictions or to extract pertinent data for compound optimization.

Here are some important issues and considerations about the interpretability of AI models.

Black-Box Nature of Complex Models:

- Opacity of Deep Learning:

Deep learning models, such as neural networks, are effective yet lack transparency. These models learn complex, non-linear correlations from vast datasets, making it difficult for researchers to understand why a given molecule is predicted to have a certain activity or binding affinity.

- Loss of Insight:

Understanding the "why" behind predictions (for example, why a given chemical structure is predicted to bind to a protein) in drug development is crucial for enhancing compounds or explaining biological phenomena. The inability to interpret data can impede decision-making in experimental design or compound optimization.

Complexity of Feature Representation:

- High Dimensionality:

AI models, particularly in drug development, frequently rely on high-dimensional feature spaces. For example, molecular descriptors (such as chemical fingerprints, electrostatic potential, or molecular weight) may be employed to represent compounds, although these

characteristics may not be intuitively or directly related to therapeutic activity. Understanding which of these features is influencing the model's forecast might be challenging.

- Non-linear Interactions:

Models can learn intricate connections between features that are difficult to explain, making it difficult to determine which chemical features contribute to a prediction, such as activity against a specific protein target.

Challenges of Compound Optimization:

I. Lack of Guidance for Optimization:

There is a lack of guidance for optimization. Without interpretability, it is difficult to grasp how to refine a molecule in order to increase its activity. Structure-activity relationship (SAR) studies are used in traditional drug discovery to repeatedly change the structure of a molecule and observe the effect on its biological activity. When AI models are deployed, it is difficult to determine whether structural modifications will result in improved results unless the model's predictions are explained clearly.

II. Rational Design Limitations:

Although AI models may propose new compounds, chemists find it challenging to justify their design due to their inability to be interpreted. This could make them less confident about using AI for tasks like de novo drug design and lead optimization[121].Notwithstanding these difficulties, CADD has enormous potential advantages in drug discovery. Accepting these limitations and continuously working to overcome them through research and innovation will allow CADD to stay at the forefront of drug discovery today and have an impact on therapies in the future.

III. Current Challenges in CADD:

Overcoming Barriers: A Changing Landscape of Challenges in Computer-Aided Drug Design although drug development has been revolutionized by advancements in computer-aided drug design (CADD), the field is not without challenges. These difficulties point to areas that are ready for more innovation, ranging from data quality to the requirement for more predictive models[122].One of the most crucial problems is guaranteeing data availability and quality. Computer predictions can be erroneous due to dataset inaccuracies, such as false chemical structures or misleading bioactivity data. Additionally, hoarding proprietary data prevents knowledge from being shared and consolidated[123]. Models with greater predictive power are still required despite developments. Sometimes, models can produce false positives or overlook real possibilities, especially when used to predict drug-target interactions[124]. Biological macromolecules such as proteins and nucleic acids are active. It is a significant computing challenge to account for this flexibility in simulations, particularly over long periods of time[125]. It is crucial to make sure that CADD approaches scale well as drug databases and models become more complex. This calls for constant algorithm optimization and the use of contemporary computational resources [126]. As multi-omics and various biological data become more prevalent, it can be difficult to integrate these disparate pieces of information in a way that enhances drug development[127]. Given that CADD often utilizes patient data, particularly in personalized medicine, safeguarding data privacy and addressing ethical issues related to data usage are essential[128]. In conclusion, while CADD advances drug research, surmounting its obstacles is essential. Addressing these difficulties directly may enable the sector to transform, adjust, and advance towards more efficient and successful drug discovery models.

Antimicrobial resistance challenge:

Limitation of CADD for antimicrobial drug discovery

The accuracy of predictive models in Computer-Aided Drug Design (CADD) is in fact a significant challenge due to the essential complication of biological systems and the limitations of computational approaches .while predictive models in CADD are valuable tools, their accuracy can be significantly increase by addressing the limitations of individual methods and integrating multiple approaches. Continuously improving scoring algorithms, leveraging hybrid and ensemble models, and refining molecular simulations will be key to advancing CADD and improving the design of effective therapeutic compounds.

Future Prospective for CADD in Antimicrobial agent Development:

With the rise in antibiotic resistance and the pressing need for new treatments, computer-aided drug design, or CADD, is becoming a more significant tool in the development of antimicrobials. Here are a few prospects for CADD in this field going forward. Computer-Aided Drug Design (CADD) appears to have a bright future, particularly in the development of novel and potent medications like antimicrobial treatments. Here's why

I. Examining New Prospects: Advancements in Computer-Aided Drug Design:

Deep learning in particular is becoming a significant component of computer-aided drug design (CADD). Neural networks can be used to predict whether a drug may be toxic and to propose new drug ideas because they are adept at identifying patterns in vast amounts of data [129]. CADD tools will concentrate on developing medications based on an individual's distinct genetic information as genetic sequencing becomes more widespread. This will result in genuinely customized medications made according to a person's genetic composition[130].Everyone can have greater access to drug discovery through collaborative and open-source platforms. These platforms can combine various fields of expertise and expedite the process of discovering new drugs by combining the knowledge and abilities of scientists from around the globe [131]. Computer-aided drug design (CADD) appears to have a bright future. CADD will enhance and help to improve healthcare for everyone by embracing new concepts and developing technology.

II. Using Global Intelligence in Computer-Aided Drug Design: Finding Unity in Diversity.

In our increasingly connected world, collaborative networks and open-source platforms are very important in computer-aided drug design (CADD). These platforms bring together the knowledge of researchers from around the world, making the drug discovery process faster, more accessible, and less expensive[132].Traditional drug discovery usually requires a lot of money and resources, which makes it limited to only certain groups. Open-source platforms change this by letting researchers from anywhere contribute to and use advanced CADD tools, no matter where they work Initiatives such as the Open-Source Drug Discovery (OSDD) initiative for TB exemplify global collaboration to achieve this objective [133].Crowdsourcing systems in computer-aided drug design (CADD) use global expertise. The problems presented on these platforms result in a variety of solutions, some of which may be unconventional but very successful. Open-source platforms ensure the continual development of CADD tools. Community-developed tools are routinely updated in accordance with user input and recent scientific advancements. In an era when

collaboration and information exchange are paramount, these CADD platforms provide optimism for an improved future. They demonstrate that collaboration and information sharing may result in a healthier planet[134].

III. **A Glimpse into the Horizon: Envisioning the Next Epoch of Computer-Aided Drug Design** :

As we approach a new era with quantum computing, these computers have the potential to greatly improve how we simulate molecules and design drugs. They offer speed and accuracy that were once thought impossible[135].As artificial intelligence (AI) continues to develop, it promises to create more advanced models for drug discovery. Soon, deep learning models will be able to better simulate how proteins fold and predict how drugs will interact with their targets, with greater accuracy[136]. Combining computer-aided drug design (CADD) with the vast and varied data from genomics, proteomics, and metabolomics (the study of genes, proteins, and metabolism) will contribute to the development of a more comprehensive approach to drug design as these fields advance. We will be better able to comprehend and take into account intricate biological systems as a result[137]. Sustainability measures may be required in future CADD models to ensure that drug discovery does not negatively impact the environment[138]. As AI becomes more involved in discovering drugs, there are more concerns about how machines make decisions, whether we can understand their choices, and if they might be biased. In simple terms, the future of computer-aided drug design (CADD) will involve both exciting innovations and important challenges related to ethics. By addressing these issues early and using new technologies, CADD can keep improving drug discovery and lead to better health for everyone[139].

IV. Incorporating Multi-scale models:

Traditional CADD focuses on primarily on molecular interactions typically at the atomic scale. However incorporating multiscale models allows for simulating hoe molecules behave not only in isolation but also within complex biological systems. This includes the interaction of drugs with entire networks of proteins, metabolites and other molecules within the cell, tissue, or organ, enhancing the accuracy of drug target interactions. Multiscale model can integrate data from genomics. Proteomics, metabolomics and other omics sciences by analyzing how a drug affects a biological systems at different levels CADD can provide more comprehensive insights into its efficacy and toxicity. Multiscale CADD will allow researchers to simulate disease progression at the molecular level (e.g. Mutations and protein misfolding) while also capturing cellular and tissue level changes. Instead on focusing only on drugs interact with a single protein or receptor, multiscale model simulate how the drugs affects entire tissue or organ. By simulating drug effects across different scales, researchers can better predict potential off-target effects and toxicity

V. Collaborative efforts for global databases :

CADD can help scientists design medicines that target specific bacteria causing infections, like eye infections. Using computer models, scientists can make sure the drugs work well and are safe for the body. CADD helps design medicines that can get into hard-to-reach places, like the eye, where infections happen. Some bacteria become resistant to drugs over time. By sharing data globally, scientists can track these changes and use CADD to create new medicines that

fight resistant bacteria. With data shared between countries, researchers can work together to design better treatments. This helps keep up with new types of bacteria and resistance. CADD can help create medicines that are tailored to individual people, based on their unique needs and the specific bacteria causing their infection. This makes treatments more effective. CADD can speed up the process of finding new drugs, which is helpful when new bacteria or resistance appears. By using CADD and global data sharing, people in all parts of the world can benefit from new and better treatments, even in places with fewer resources.

VI. Understanding Bacteria at the Core:

By analyzing **bacterial genomes** (complete genetic material of bacteria), CADD can help identify the most suitable drug targets. This makes the drug design process more precise. CADD can help identify bacterial proteins and other biomolecules as potential targets for drug developments. In future it will aloe for a deeper understanding of bacterial pathways and interactions at a molecular level, providing critical insights into how bacterial processes can be disrupted. CADD techniques like molecular docking and molecular dynamics simulations allow researchers to model how bacterial proteins interact with potential drugs. This can provide a more detailed understanding of bacterial virulence factors, biofilm formation, andother essential processes that contribute to pathogenicity

VII. Personalized medicine approaches :

CADD can help design antimicrobial drugs based on a person's specific genetic makeup. This means a person's unique biology and how they respond to infections can guide the development of the most effective medicine for them. With personalized medicine, CADD can help identify the exact bacteria causing the infection in a patient and design drugs that target those bacteria specifically. This reduces the chances of overusing antibiotics and helps avoid unnecessary side effects. By using CADD, doctors could predict the right dosage of antimicrobial drugs based on an individual's biology. This means the treatment would be more effective, and patients would not take higher doses than necessary. CADD can predict how a person's body will respond to a certain antimicrobial drug. This helps doctors choose the right treatment before it is even given, making the treatment process more efficient and precise. Personalized medicine can help prevent antibiotic resistance by designing treatments that are more targeted and effective against specific bacteria, reducing the need for broad-spectrum antibiotics. Using CADD, scientists can quickly create new drugs or adjust existing ones to fit a person's specific needs, especially when infections are caused by rare or resistant bacteria. If new bacteria strains appear, CADD allows for faster design of antimicrobial agents tailored to combat those specific strains, making the healthcare system more agile in fighting infections.

VIII. **Smart Approaches:**

Techniques like these are becoming popular in drug discovery:

- Subtractive Genomics: Finds proteins that exist only in bacteria (the pathogen) and not in humans, making them ideal drug targets.
- Structural Bioinformatics: Predicts the 3D structure of molecules like proteins, which helps in designing drugs that fit perfectly into these structures.Metabolic Pathway Analysis: Studies the chemical processes inside cells to identify unique molecules in bacteria that can be targeted.

Recent advances in CADD as Antimicrobial agents:

Machine learning & Artificial Intelligence Integration as Antimicrobial agents:

Antimicrobials are pharmacological agents used to treat and prevent infections induced by bacteria, fungi, viruses, and parasites in people, animals, and plants. Sir Alexander Fleming underscored the need of mitigating antibiotic resistance in his Nobel Prize address[140]. Antimicrobial resistance (AMR) occurs when infectious bacteria fail to react to antimicrobial treatments. Treatment failure, the proliferation of the infectious disease, severe sickness, and potential mortality are possible results of this[141]. The two most common resistant infections in healthcare environments are bacteria and fungus. Patients infected with resistant bacteria or fungi have worse clinical outcomes compared to those infected with non-resistant strains of the same pathogens[142]. By 2050, antimicrobial resistance (AMR) is projected to incur costs of $100 trillion and cause 10 million deaths per year if unmitigated[143]. In 2019, the worldwide toll of bacterial antimicrobial resistance (AMR) reached 4.95 million fatalities, including 204 nations and territories, 23 bacterial pathogens, and 88 drug-pathogen combinations. The majority of these patients succumbed to bloodstream and lower respiratory tract infections induced by drug-resistant bacteria, with a peak fatality rate of 27.3 per 100,000 patients. In clinical practice, machine learning (ML) has potential as a transformative instrument for decision assistance. Presently, clinical guidelines and the experience of individual physicians inform diagnosis, treatment, and prognosis; this approach to clinical practice is termed "knowledge driving decision," synonymous with "expert system." Nonetheless, real patient situations are often more complex than a solitary suggestion or the anticipations of an individual physician. While increased specialization promotes the progress of contemporary medicine, it also complicates physicians' ability to comprehensively evaluate patients outside their own domain of competence during consultations. Machine learning can rapidly analyses all patient characteristics after training on extensive datasets, then using a trained algorithm to integrate this information to facilitate decision-making. The US Food and Drug Administration has so far endeavored to tackle difficulties related to medical picture interpretation, illness diagnosis, and patient care by sanctioning ML-based technology. Machine learning algorithms, such as deep learning, are more adept at managing intricate and diverse patient attributes to enhance medical treatment compared to rule-based expert systems or novice physicians. Moreover, machine learning is used in the diagnosis, prognosis, and therapy decision-making of infectious disorders[144]. For example, it may accurately predict sepsis with an area under the curve (AUC) between 0.68 and 0.99[145], classify infections at admission[146], and recommend antibiotics to support antibiotic stewardship[147]. Health information systems (HIS) are widely used, and because of their convenience, easier gathering, accumulating, and accessing of medical data. A large amount of data provides a platform for creating machine learning tools for clinical use. We can examine and infer information from data that would otherwise be unavailable to humans thanks to machine learning. There are countless problems that can be solved by applying machine learning, but they all share certain characteristics[148].First, even if there is a known solution to the problem, it is either impractical or would take a lot of resources to turn it into a computer program. Humans, for instance, can quickly distinguish a dog from a variety of other four-legged animals, but it would be nearly impossible to write a computer program that would explicitly list every feature of a dog and how it differs from other animals of a similar nature. However, with today's ML software tools, it might only take a few lines of code to train an ML algorithm to recognize a dog. Second, ML algorithms may be useful for

solving complex problems for which conventional approaches have not been successful[149].For example, deep learning systems can be used to master the ML model in real-world settings, but it can also direct researchers toward a more thorough comprehension of the system under study. ML, for example, can direct mathematicians by identifying relationships and patterns among mathematical objects that may result in the development of novel theories and hypotheses[150].

Machine learning software:

- The TensorFlow (https://www..... org/)[151]Tensorflow. Google created TensorFlow, which is compatible with Python, C++, Julia, and Java, among other programming languages.
- Keras (https: //keras. io/). An extensively used and intuitive Python interface for the TensorFlow library is called Keras. https://scikit-learn. org/[152]
- Scikit-learn. The Scikit-learn Python library includes a large number of machine learning algorithms that are tailored for Python data structures. It is also possible to use Scikit-learn with wrappers for other programming languages, like Julia. www.pytorch.org/, or PyTorch[153]
- Facebook created the ML framework PyTorch, which is mainly for Python but also has a C++ version[154].

Artificial Intelligence:

Combining cutting-edge technologies, like artificial intelligence (AI), presents exciting prospects for personalized medicine, drug discovery, surveillance, and diagnostics. The use of AI in drug development and discovery to fight antibiotic resistance is examined in this narrative review. It looks at different uses of AI in lead optimization, compound screening, target identification, and repurposing. The review also discusses ethical concerns and the limitations and challenges of AI in AMR-focused drug discovery. AI can be used to improve existing drugs, speed up the development of new antimicrobial agents, and effectively combat the growing threat of antimicrobial resistance.

AI Discipline and methods of AI



Fig-7: AI in antimicrobials drug discovery

The digitalization of data in the pharmaceutical sector has grown dramatically in the last several years. This digital transformation poses difficulties for the acquisition, analysis, and application of knowledge in order to effectively address complex clinical issues. Increasing interest in AI is a result of its improved automation in handling massive amounts of data. Artificial intelligence (AI), a technology-based system, mimics human intelligence using a

range of advanced tools and networks without completely replacing people's physical presence[155]. This review examines how the pharmaceutical industry is continuously expanding its use of AI. To make decisions on their own, artificial intelligence (AI) uses hardware and software that can analyze and learn from input data. As the McKinsey Global Institute predicts, the swift development of AI-guided automation will profoundly change the way society views work[156]. AI encompasses the fundamental paradigms of machine learning (ML), deep learning (DL), and language large models in addition to several methodological domains like knowledge representation, reasoning, and problem solving.

AI Applications in AMR:

Traditional Machine Learning for Antimicrobial Compound Identification: Machine learning, a branch of artificial intelligence, has become an effective instrument for drug discovery, particularly in the identification of antimicrobial compounds. Utilizing extensive datasets, computational algorithms, and pattern recognition, machine learning methods enable the fast and effective detection of prospective antibacterial drugs. This section examines the function of machine learning in the identification of antimicrobial substances and offers pertinent references to substantiate its use.

1. **Data-driven Approaches:**

   Algorithms employing machine learning can analyze vast amounts of data, including chemical structures, biological activity profiles, and genomic information, to identify trends and relationships pertaining to antimicrobial activity. Utilizing presently accessible data, machine learning algorithms can forecast the antibacterial efficacy of novel drugs and priorities candidates for further experimental validation[157–160].

2. **Virtual Screening and Drug Repurposing:**

   Machine learning methodologies facilitate virtual screening, a computer strategy for discovering prospective antimicrobial agents from extensive chemical repositories. Machine learning algorithms can quickly screen millions of compounds and rank them based on their potential antibacterial activity by using established antimicrobial compounds and their characteristics for model training. Machine learning may facilitate drug repurposing by discovering current drugs that may exhibit antibacterial characteristics[161,162].

3. **Machine learning :**

Machine learning techniques need instructive features or descriptors to extract pertinent aspects of antibacterial substances. Molecular fingerprints, physicochemical qualities, and structural fragments are examples of the many molecular descriptors that machine learning algorithms may use as input features. The compounds' chemical space can be represented more easily and their antimicrobial properties can be predicted more easily thanks to these descriptors[163,164].

4. **Optimization and Predictive Models:**

Machine learning algorithms can create prediction models that categories substances as either non-antimicrobial or antimicrobial depending on their characteristics. These models may be trained using labelled datasets, and optimization can enhance their generalizability and accuracy. Moreover, via molecular design and virtual screening, machine learning may facilitate the optimization of chemical structures of compounds to enhance their antibacterial efficacy[165,166].

5. **Prediction of Antibiotic Resistance:**

Machine learning techniques may be used to anticipate and analyze antibiotic resistance. Machine learning methods may uncover genetic markers and patterns linked to resistance mechanisms by analyzing genomic data from resistant strains. This understanding may guide the creation of innovative antimicrobial agents or approaches to address resistance[167,168].

Additional use of AI to fight AMR

AI in Genomics, Proteomics, and High-Throughput Screening:

Proteomics, genomics, and high-throughput screening (HTS) are crucial areas in biomedical research and drug discovery. The way scientists evaluate and interpret vast amounts of biological data has been completely transformed by the introduction of AI into these domains, producing more accurate and efficient findings. Studies have shown that AI has spurred innovation across a range of fields, such as proteomics, genomics, and high-throughput screening.

A genomics analyzer with artificial intelligence:

Large-scale genomic data, such as DNA sequencing and gene expression data, can be analyzed by AI algorithms to find trends and correlations that could be important for the diagnosis, prognosis, and treatment of diseases. Researchers can find disease-causing mutations and possible

Treatment targets with the aid of AI, which can also assist in the interpretation of genomic variants. AI can assist in comprehending gene networks and biological processes by using genomic data to predict gene functions and regulatory elements[169].

Proteomics Analyzer with AI:

Algorithms in Proteomics Analyzer, equipped with AI capabilities, may evaluate proteomics data, including protein expression levels and post-translational changes, to discern biomarkers for illness diagnosis, prognosis, and therapy. Artificial intelligence can elucidate drug-target interactions and protein functionality, in addition to forecasting protein shapes and interactions. Artificial Intelligence (AI) may assist in finding possible treatment targets by analyzing proteomics data and pinpointing proteins involved in disease processes. Overall, the use of AI in proteomics, genomics, and high-throughput screening has markedly enhanced the precision and efficacy of data processing, resulting in improved results for biomedical research and drug development[170].

AI-powered screening to speed up drug discovery:

AI-powered screening techniques use machine learning (ML) algorithms to evaluate big data sets, forecast the characteristics of compounds, and rank molecules for additional experimental verification. With the help of pertinent references, this section explores the uses of AI-powered screening in drug discovery.

Virtual Screening:

AI systems can conduct virtual screening to computationally assess extensive libraries of chemicals as possible therapeutic options. Machine learning models, such as SVM, random forests, and deep learning architectures, can forecast the probability of a compound's activity against a particular target by examining biological data, physicochemical attributes, and molecular structures. This methodology priorities compounds for experimental testing, hence minimizing the time and expenses linked to conventional screening techniques[171].

HTS Data Analysis:

AI systems can analyze data produced by high-throughput screening programs that swiftly evaluate hundreds of chemicals against a target. Artificial intelligence (AI) models may discern active compounds, comprehend structure-activity correlations, and forecast the potency of untested compounds by using machine learning methodologies such as regression, classification, and clustering on high-throughput screening (HTS) data. This enables informed decision-making and assists scientists in concentrating on the most promising molecules[172]. **De Novo Design:**

Techniques driven by artificial intelligence enable de novo drug creation by creating new chemical structures with certain attributes. Generative models, such as variational auto encoders (VAEs) and generative adversarial networks (GANs), which learn from established chemical libraries, may synthesize novel compounds with desirable characteristics. AI algorithms may integrate generative models with reinforcement learning approaches to iteratively create and enhance drugs based on target interactions and desired pharmaceutical features[173].

Drug Repurposing:

AI algorithms can analyze extensive clinical and biological datasets to uncover possible new uses for previously approved medications. Through the amalgamation of data from many sources, including pharmaceutical databases, electronic health records, and genetic information, AI models may forecast novel drug-disease correlations and repurpose existing drugs for alternative uses. This strategy enables the rapid identification of viable therapy possibilities, hence minimizing the time and expense associated with preclinical and clinical development[174].

Predictive ADME-Tox Modeling:

Artificial intelligence methodologies can forecast the ADME-Tox (absorption, distribution, metabolism, excretion, and toxicity) characteristics of a substance. AI models can forecast the toxicological and pharmacokinetic characteristics of novel substances by using extensive databases of experimental data and chemical attributes. This facilitates the identification of possible safety issues and optimizes lead compounds early in the drug development process[175].

Deep learning in medication design and optimization:

Deep learning models can synthesize novel compounds with specific attributes by analyzing extensive chemical databases for trends. Generative models, such generative adversarial networks (GANs) and variational auto encoders (VAEs), may generate structurally varied molecules with targeted chemical attributes. These produced molecules may function as building blocks for further synthesis and optimization[176]. Deep learning algorithms can effectively predict several chemical characteristics, including solubility, bioactivity, toxicity, and binding affinity. Deep learning algorithms trained on extensive datasets of chemical structures and their corresponding properties may predict novel compounds and reveal intricate linkages. These predictions facilitate the efficient allocation of time and resources by prioritizing compounds for synthesis and screening[177]. Deep learning models may be used for virtual screening, a process that computationally evaluates extensive collections of substances to discover possible candidates against particular targets. Convolutional Neural Networks (CNNs) and Recurrent Neural Networks (RNNs) can analyze molecular structures, protein-ligand interactions, and binding affinities to priorities compounds according to their binding

probability to a target. This approach aids in the identification of prospective lead compounds for further examination[178]. Deep learning algorithms can analyze extensive biological and chemical data to identify novel therapeutic applications for previously approved medications. Deep learning algorithms may integrate gene expression patterns, drug-protein interactions, and disease networks to identify possible drug-disease connections and repurpose licensed drugs for novel purposes[179].

Quantum Computing:

Quantum computing (QC) is a cutting-edge domain of computation that employs principles from quantum physics to manipulate data in fundamentally distinct manners compared to traditional computers. Qubits serve as the fundamental components of quantum information in quantum computing, analogous to the bits used in conventional computing[180]. Qubits use quantum characteristics such as entanglement and superposition, in contrast to conventional bits, which may just represent 0 or 1. Superposition enables qubits to occupy a state that concurrently embodies both 0 and 1, rather than possessing a single, unique state. Quantum computers, owing to their ability to handle vast quantities of data simultaneously, may resolve complex problems more rapidly than conventional computers. Moreover, qubits may get entangled even when separated by significant distances, indicating that the state of one qubit may be contingent upon the state of another[181]. Qubits are unique in this interconnectedness, which makes it possible to perform intricate computational operations that conventional bits cannot. These characteristics allow quantum computers to outperform classical computers in solving specific kinds of problems, like factoring big numbers or simulating quantum systems.



Fig-8: Steps of Quantum Computing

QC Techniques in Medical Research:

Table-4: QC in Medical Research

Aspect	Quantum computing	Classical computing
Data processing speed	Can process complex datasets exponentially faster due to superposition & parallelism	Limited to sequential processing, leading to longer computation times for large datasets.
Complex problem solving	Efficiently solves problems involving multiple variables and probabilities, such as molecular interactions.	Struggles with NP-hard problems, requiring extensive computational resources and time.
Drug discovery	Accelerates molecular simulations, enabling the identification of potential drug candidates more quickly	Slower drug discovery processes, which are reliant on trial-and-error approaches And classical simulations.
Genomics analysis	Enhances the ability to analyze complex genetic data, improving understanding of genetic interactions	Faces limitations in handling vast genomic datasets efficiently.
Medical imaging	Improves imaging techniques through quantum-enhanced methods, leading to higher Resolution and better diagnostic capabilities.	Conventional imaging methods may not capture fine details or require extensive processing time.
Personalized medicine	Optimizes treatment plans by considering numerous factors simultaneously, leading to tailored therapies.	Typically utilizes standard treatment protocols, which may not account for individual patient variability
AI & Machine Learning	Enhances AI models through faster data training and improved pattern recognition in diagnostics.	Limited by classical computing power, which may slow down AI model training and analysis
Resource Efficiency	Potentially reduces the number of computational resources needed for complex simulations And analyses.	Often requires significant computational resources and time for complex healthcare tasks.
Security & Encryption	Offers advanced encryption methods through quantum key distribution, enhancing data security	Vulnerable to classical hacking methods, with standard encryption potentially

		Susceptible to breaches.

Quantum Algorithms for Drug development:

Quantum computing has produced advanced algorithms capable of transforming the drug development process by enhancing the efficiency of molecular modeling. Grover's approach is designed to expedite the search of unsorted databases compared to traditional algorithms[182]. This technique may be used to scan extensive chemical databases for possible drug candidates that meet particular molecular criteria in the realm of drug development. The Variational Quantum Eigen solver (VQE) is an important quantum method especially effective for modelling the electronic structure of molecules[183].

Quantum Machine Learning (QML) in Healthcare:

QML is an innovative domain in healthcare that leverages the potential of quantum computing to augment the functionalities of conventional machine learning models[184]. Quantum algorithms enable QML to handle and analyse extensive, intricate datasets more efficiently than conventional systems. One use is in diagnostic analytics, where quantum-enhanced models may more swiftly and accurately identify patterns in medical data, such as radiological scans[185]. QML may assist physicians in recognizing subtle illness symptoms that conventional models may overlook, hence enhancing the precision of early cancer diagnosis via the analysis of genetic data or medical imaging[186]. QML is enhancing predictive analytics, allowing more precise forecasts of patient outcomes and disease development[187].

Quantum Imaging Techniques:

Quantum principles has the ability to modernize medical imaging through enhancing the precision and resolution of imaging modalities, such as magnetic resonance imaging (MRI). Quantum computers and quantum sensors provide the potential to substantially improve the accuracy of traditional MRI scans, which produce images of the inner workings of the body using radio waves and magnetic fields[188]. A significant accomplishment in this field facilitating earlier and more precise diagnosis of anomalies such as tumours is the emergence of quantum-enhanced MRI, which employs quantum coherence and entanglement to produce higher-resolution pictures[189].

Quantum-Optimized Treatment Plans:

Because QC provides previously unheard-of computational power for intricate computations, it has enormous potential for improving radiotherapy treatment plans and personalized medicine. The objective of radiotherapy is to accurately target cancerous tissues while causing the least amount of harm to nearby healthy tissues; this is accomplished by figuring out the best radiation dose distribution[190]. These dose distributions can be optimized much more effectively than with traditional techniques thanks to quantum computers' capacity to process massive, multidimensional datasets concurrently. This makes it possible to administer radiation therapy more precisely and individually, which lowers side effects and enhances patient outcomes. Quantum techniques can be applied in personalized medicine to customize care according to a patient's genetic profile[191].

Advantages of Quantum Computing:



Fig-9: Advantages of Quantum Computing

Useful QC Applications in the Medical Field:

Above Figure illustrates the various uses of QC in medicine, emphasizing how its increased computational power and efficiency could transform industries like drug development, genomics, medical diagnostics, AI-enhanced healthcare, and radiotherapy. Each branch stands for a crucial area where QC is expected to significantly advance, enhancing clinical practice and medical research accuracy and speed.

Molecular Simulation and Drug Design:

QC is transforming molecular modelling and drug design by markedly expediting the drug discovery process. Conventional approaches of modelling chemical interactions and forecasting drug interactions with biological targets are resource-intensive and protracted, particularly for intricate structures[192]. Quantum computers can mimic interactions at the quantum level, enabling them to generate more precise models of molecular behavior in a markedly reduced timeframe compared to conventional computers[193]. Researchers may now more swiftly and precisely identify prospective drug candidates, therefore reducing the time and expense involved in drug development. Biogen's partnership with Accenture Labs exemplifies the use of quantum algorithms to expedite the discovery of therapies for neurological illnesses, including Parkinson's disease, Alzheimer's disease, and Lou Gehrig's disease. Moreover, Modern and IBM are collaborating to investigate quality control for mRNA vaccine development[194]. These real-world instances illustrate that quantum simulations extend beyond theoretical applications; they are actively revolutionizing the pharmaceutical sector by expediting the discovery of novel medications and perhaps quickening the availability of life-saving therapies[195].

Personalized medicine and genomics:

Quantum computing has the potential to transform genomics and personalized medicine by facilitating the investigation of intricate genetic relationships at a scale that is now unachievable with conventional computers. The intricacy of human genetics, characterized by interrelated components and extensive data, necessitates substantial processing ability to comprehend gene interactions and their impact on illness. The capacity to more effectively simulate these intricate interactions enables quantum computers to discern patterns and genetic alterations that lead to illnesses such as cancer, Alzheimer's, and cardiovascular disease. Quantum models in personalized medicine enable the optimization of treatment regimens and the creation of individualized therapies based on genetic makeup via the analysis of extensive datasets, including a patient's genetic data, medical history, and environmental influences. This tailored

strategy enhances treatment efficacy by guaranteeing that medicines are both targeted and sufficiently adaptive to the unique genetic profile of each patient. An instance is Strelchuk et al. The initiatives of Cambridge QC to use quantum technology for genetic research and its relationship with the Q4Bio program to investigate DNA diversity mapping using QC exemplify collaborative efforts[196].

Diagnostics for Medicine:

Quality control is increasingly becoming a potent instrument in medical diagnostics, as it improves pattern recognition and data analysis for the early identification of disorders. Quantum algorithms, like quantum neural networks and quantum support vector machines, capable of detecting nuanced patterns often overlooked, may expedite the analysis of intricate medical information. This expertise is particularly advantageous in diagnosing conditions such as cancer and neurological illnesses, when early identification is crucial for favorable treatment results. Quality control may be used to analyse extensive genetic or imaging datasets, such as MRI scans, to detect early indicators of illnesses such as Parkinson's or Alzheimer's disease. Quantum algorithms in oncology may facilitate the early diagnosis of malignant cells by identifying unique patterns in genomic or imaging data that are too intricate for traditional computers to handle efficiently. The Quantum AI team at Google and D-Wave are investigating how quantum computing might accelerate early cancer detection, enabling more precise and prompt diagnoses via improved pattern recognition and the processing of extensive medical information. In D-Wave's implementation, the term "quantum speedup" refers to the ability of quantum annealers to solve particular types of difficult optimization problems faster than traditional supercomputers or classical algorithms. Quantum tunneling, a unique type of quantum phenomenon that permits qubits to change states even in the presence of an energy barrier, is used by the D-Wave system. Compared to conventional brute-force methods, this enables the system to examine multiple possible solutions simultaneously, leading to a noticeably shorter time needed to find the optimal solution[197].

Enhancement of AI in Healthcare through QC:

The capabilities of AI models in the healthcare industry could be greatly increased by combining QC and AI. Large and complicated datasets can be processed more quickly by quantum AI than by classical AI models, which can improve fields like radiology, where quantum-enhanced algorithms can offer more precise image analysis and diagnostics[198]. By empowering AI models to more quickly and accurately analyze massive, multifaceted datasets, including genetic information, patient histories, and environmental factors, Additionally, QC can enhance predictive analytics in healthcare. This enables more accurate and early identification of patients who are at risk for specific diseases or complications, as well as better predictive modeling. Additionally, quantum-enhanced AI models allow for real-time insights and treatment plan optimization regarding patient response to treatments. Companies such as IBM, Google, and Rigetti Computing are leading research that integrates quantum computing and artificial intelligence to enhance healthcare, with applications including diagnostic imaging, personalized medicine, and drug development.

Radiotherapy Monte Carlo Simulation:

The Monte Carlo simulation is an effective computer method often used in radiotherapy for precise dosage estimation and treatment planning. The Monte Carlo approach, owing to its stochastic characteristics, can precisely represent the distribution of radiation doses inside a

patient's body by simulating the intricate interactions between radiation particles and matter[199]. This is especially vital for sophisticated radiotherapy methods like as intensity-modulated radiation therapy and proton therapy, where accurate dose estimations are essential to optimizetumor management while reducing harm to healthy tissues[200,201]. The Monte Carlo simulation, which considers several physical processes such as scattering, absorption, and secondary particle formation, is one of the most precise techniques for calculating radiation doses in heterogeneous tissues. Located in the pulmonary region of the head and neck. Despite the computational complexity of Monte Carlo simulations, advancements in quantum computing and high-performance computing are decreasing calculation durations, making this methodology appropriate for clinical use[202]. Incorporating quantum algorithms into Monte Carlo simulations enables researchers to enhance the speed of these computations[203]. This may lead to real-time adaptive radiotherapy, which modifies treatment regimens dynamically according on the patient's anatomy during administration.

Effective use of CADD in drug development and discovery:

Computer-Aided Drug Design (CADD) has been used into successful drug development and discovery efforts, underscoring the importance of these methodologies in these fields. Recent study indicates that CADD approaches have identified over 70 clinically authorized medicines[204,205]. Pharmacophore modelling and structure-based virtual screening (SBVS) approaches were used to identify the antibiotics isoniazid for tuberculosis and norfloxacin for urinary tract infections[206]. Vaborbactam was identified by a synthesis of molecular dynamics and molecular docking. In 2017, it received approval from the US FDA as a strong inhibitor of serine β-lactamases in carbapenem-resistant Enterobacteriaceae[207]. A nonsteroidal anti-inflammatory medication targeting the protein cyclooxygenase 2, flurbiprofen, was produced using the MD method. Dorzolamide, derived via fragment-based virtual screening, is now used for the treatment of cystoid macular edema and glaucoma. Employing CADD approaches, several commercially accessible pharmaceuticals were found, including oseltamivir and zanamivir, which act as inhibitors of the influenza virus's neuraminidase[208]. Similarly, CADD approaches have facilitated the advancement of S.O, captopril (which inhibits angiotensin-converting enzymes), norfloxacin (which targets topoisomerase II and IV), and ritonavir. Oselusi and associates. Other studies have comprehensively investigated tyrosine kinase inhibitors such as fedratinib hydrochloride, axitinib, lorlatinib, adagrasib, entrectinib, zanubrutinib, saquinavir, nelfinavir (which inhibits HIV-1 protease), indinavir, among others[209].

Target identification and Biomarker Discovery

It is the first important step in drug discovery is finding and confirming the right target. Network-based drug discovery can also be used to study target identification. Many new technologies have been developed to study targets. Genomic and proteomic methods are the main tools for identifying them. This field combines various types of information related to drug-protein and protein-disease interactions. It relies on strong collaboration between databases and connections across different biological areas, such as genomics, transcriptomics, proteomics, metabolomics, microbiome studies, and pharmacogenomics. The success of this approach depends on advanced computational and systems biology tools to analyze and interpret the data[210,211]. These methods, such as linking drug effects with genetic information,

can help create computer-based models for identifying drug targets. A recent network-based approach combined large-scale structural genomics with disease association studies to create a 3D map of human protein interactions. This helped identify potential genes linked to diseases that were previously unknown, along with possible molecular mechanisms[212]. Today, information technologies are more important than ever for gaining a deep understanding of disease processes and characteristics[213]. A proteomic method for finding binding proteins of a small molecule works by comparing protein expression in cells or tissues with and without the molecule. However, this approach has not been very successful for target discovery because it is difficult and time-consuming[214]. In addition to experimental methods, various computer-based (in silico) tools have been developed to identify targets. These tools are classified into sequence-based and structure-based approaches. The sequence-based approach helps identify targets by providing functional details about target candidates and their roles in biological networks. For diseases caused by bacteria or viruses, unique targets can be found in the pathogens by comparing their genetic information with that of humans[215]. In theory, this method can identify all targets in a pathogen. For diseases that originate within the body, targets can be found by comparing the genetic differences between healthy and diseased tissues. A good example of this is the discovery of new steroid targets using a combination of bioinformatics and functional analysis of hormone response elements[216]. One computational method, known as reverse docking (or inverse docking), works by doing the opposite of traditional docking. Instead of testing different ligands on a specific target, it docks a biologically active compound into the binding sites of all available 3D protein structures in a database. The identified proteins, called "hits," can then be tested further in experiments to confirm their potential as targets[217]. Protein structures are usually taken from the Protein Data Bank (PDB) or created using protein structure prediction methods. For example, using a part of the Protein Data Bank (PDB), Paul et al. successfully identified the correct targets for four different ligands using the reverse docking method[218]. A reverse docking web server called Target Fishing Dock (TarFisDock) was developed to identify new drug targets. To support this, a potential drug target database (PDTD) was created. The target proteins in PDTD were gathered from research articles and online databases like Drug Bank, while their structures were obtained from the Protein Data Bank (PDB).

Table-5: Web-accessible databases for drug target identification:

Utility	**Url**
Human metabolome data	http://www.hmdb.ca
***In silico* target identification**	http://www.dddc.ac.cn/pdtd http://www.genome.jp/kegg http://www.geneontology.org
Pathway analysis	http://www.re.actome.org http://www.pantherdb.org http://www.biocarta.com http://ingenuity.com
Chemo genomic data	http://www.ebi.ac.uk/chembldb http://www.pubchem.ncbi.nlm.nih.gov

Drug target database	http://www.drugbank.ca
Protein data bank	http://www.pdb.org
Disease specific target database	http://www.thomsonreuters.com/meacore
pharmacogenomics data	http://www.pharmgkb.org
Multi-level drug data	http://www.r2d2drug.org/DMC.aspx
Comparative toxicogenomic database	http://www.ctdbase.org
Target-toxin database	http://www.13db.org
Protein expression information	http://www.proteinatlas.org
Therapeutics target database	http://bidd.nus.edu.sg/grooup/cjttd

A biomarker is something that can be measured to show what's happening in the body. It can indicate normal body functions, diseases, or how the body reacts to a treatment or exposure. Examples of biomarkers include molecules, tissue changes, medical images, or body functions. However, a biomarker does not describe how a person feels, moves, or how long they live. The BEST glossary classifies biomarkers into seven types: risk/susceptibility, diagnostic, tracking, prognostic, predictive, treatment response (pharmacodynamics), and safety. Qualified biomarkers can give important information that helps make regulatory decisions more certain during drug development. When a biomarker is qualified, it means it has gone through an official approval process to confirm that it can be trusted for a specific purpose in developing and reviewing medical products. However, it's important to understand that the qualification applies to the biomarker itself, not the method used to measure it.The qualification process is a collaborative effort in which the Biomarker Qualification Program partners with requestors to facilitate biomarker development. Frequently, multiple stakeholders collaborate within working groups or consortia to advance a biomarker toward qualification. This strategy enables resource sharing and alleviates the burden on individual contributors. Consequently, it may encourage participants to engage in a Drug Development Tool (DDT) initiative, even when resources are limited.Under the 21st Century Cures Act, biomarker qualification follows a three-stage submission process to establish a biomarker for regulatory purposes. To ensure comprehensive and high-quality submissions, the FDA determines whether to accept or notaccept them. This decision is conveyed to the requestor through a letter that provides feedback and suggestions for further biomarker advancement. Throughout this process, requestors have opportunities to collaborate with CDER to address various aspects of biomarker development.



Fig-10: Key steps of Biomarker Discovery

CONCLUSION:

Computer-aided drug design is a multidisciplinary field that combines advancements from various scientific domains and employs diverse methods and strategies. Its primary aim is to accelerate and optimize the discovery of new biologically active compounds. However, these approaches are not a substitute for experimental testing. The goal of CADD is to generate hypotheses about potential new ligands and their interactions with biological targets. It is believed that these methods can significantly reduce the number of compounds that need to be synthesized and tested for biological activity, potentially by up to two orders of magnitude. CADD can accelerate the discovery of new molecules to combat antimicrobial computational tools can predict resistance mechanisms, enabling the design of drugs that target resistant microbes more effectively. Combining CADD with AI can improve the accuracy and speed of drug discovery by analyzing large datasets and predicting potential drug candidates. Enhanced 3D structural analysis of microbial targets through CADD allows precise targeting, reducing the likelihood of side effects and increasing drug specificity. CADD reduces the time and resources needed for traditional experimental approaches, making drug development more economical. Computational tools can be utilized to design tailored treatments based on individual patient data and specific microbial infections. CADD can assist in predicting synergistic effects of drug combinations, offering innovative approaches to tackle multi-drug-resistant microbes. Computational techniques can identify and optimize natural compounds with antimicrobial properties, providing a sustainable source of new drugs. CADD facilitates collaboration by allowing researchers worldwide to share models, datasets, and computational tools to address global challenges like antimicrobial resistance. With continuous advancements in computational power and algorithms, CADD holds promise for revolutionizing antimicrobial drug development, making it faster, cheaper, and more precise.

References:

(1) Sarak, A. B.; Dabholkar, R. P. Computational Approaches in Drug Design Molecular Docking Studies of Ace Inhibitors on Angiotensine Converting Enzyme. *Int. J. Innov. Sci. Res. Technol. IJISRT***2024**, *9* (12), 722–730. https://doi.org/10.5281/zenodo.14540188.

(2) Tardif, J.-C.; L'allier, P. L.; Ibrahim, R.; Grégoire, J. C.; Nozza, A.; Cossette, M.; Kouz, S.; Lavoie, M.-A.; Paquin, J.; Brotz, T. M.; Taub, R.; Pressacco, J. Treatment with 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients with Recent Acute Coronary Syndrome. *Circ. Cardiovasc. Imaging***2010**, *3* (3), 298–307. https://doi.org/10.1161/CIRCIMAGING.110.937169.

(3) *Tools for ligand based drug discovery*. https://zenodo.org/records/4727545 (accessed 2025-02-11).

(4) Antimicrobial Resistance Collaborators. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. *Lancet Lond. Engl.***2022**, *399* (10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0.

(5) Dadgostar, P. Antimicrobial Resistance: Implications and Costs. *Infect. Drug Resist.***2019**, *Volume 12*, 3903–3910. https://doi.org/10.2147/IDR.S234610.

(6) Abushaheen, M. A.; Muzaheed; Fatani, A. J.; Alosaimi, M.; Mansy, W.; George, M.; Acharya, S.; Rathod, S.; Divakar, D. D.; Jhugroo, C.; Vellappally, S.; Khan, A. A.; Shaik, J.; Jhugroo, P. Antimicrobial Resistance, Mechanisms and Its Clinical Significance. *Dis. Mon.***2020**, *66* (6), 100971. https://doi.org/10.1016/j.disamonth.2020.100971.

(7) De Oliveira, D. M. P.; Forde, B. M.; Kidd, T. J.; Harris, P. N. A.; Schembri, M. A.; Beatson, S. A.; Paterson, D. L.; Walker, M. J. Antimicrobial Resistance in ESKAPE Pathogens. *Clin. Microbiol. Rev.***2020**, *33* (3), e00181-19. https://doi.org/10.1128/CMR.00181-19.

(8) Peterson, E.; Kaur, P. Antibiotic Resistance Mechanisms in Bacteria: Relationships Between Resistance Determinants of Antibiotic Producers, Environmental Bacteria, and Clinical Pathogens. *Front. Microbiol.***2018**, *9*, 2928. https://doi.org/10.3389/fmicb.2018.02928.

(9) Press, D. *Drug Design, Development and Therapy - Dove Press*. https://www.dovepress.com/drug-design-development-and-therapy-journal (accessed 2025-02-12).

(10) Joy, A.; Balaji, S. Drug-Likeness of Phytic Acid and Its Analogues. *Open Microbiol. J.***2015**, *9* (1), 141–149. https://doi.org/10.2174/1874285801509010141.

(11) Cavasotto, C. N.; Phatak, S. S. Homology Modeling in Drug Discovery: Current Trends and Applications. *Drug Discov. Today***2009**, *14* (13–14), 676–683. https://doi.org/10.1016/j.drudis.2009.04.006.

(12) *EasyModeller: A graphical interface to MODELLER | BMC Research Notes | Full Text*. https://bmcresnotes.biomedcentral.com/articles/10.1186/1756-0500-3-226 (accessed 2025-02-11).

(13) Schneider, G.; Fechner, U. Computer-Based de Novo Design of Drug-like Molecules. *Nat. Rev. Drug Discov.***2005**, *4* (8), 649–663. https://doi.org/10.1038/nrd1799.

(14) Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening. *J. Med. Chem.***2004**, *47* (7), 1750–1759. https://doi.org/10.1021/jm030644s.

(15) Agu, P. C.; Afiukwa, C. A.; Orji, O. U.; Ezeh, E. M.; Ofoke, I. H.; Ogbu, C. O.; Ugwuja, E. I.; Aja, P. M. Molecular Docking as a Tool for the Discovery of Molecular Targets of Nutraceuticals in Diseases Management. *Sci. Rep.***2023**, *13* (1), 13398. https://doi.org/10.1038/s41598-023-40160-2.

(16) *Downloads – PyRx – Python Prescription*. https://pyrx.sourceforge.io/downloads/ (accessed 2025-02-11).

(17). https://www.3ds.com/products/biovia/discovery-studio/visualization.?wockw=products%20OR%20biovia%20OR%20discovery%20studio%20OR%20visualization. (Accessed 2025-02-11).

(18) *PyMOL | pymol.org*. https://www.pymol.org/ (accessed 2025-02-11).

(19) *Downloads – AutoDock Vina*. https://vina.scripps.edu/downloads/ (accessed 2025-02-11).

(20) *HADDOCK Web Server*. https://rascar.science.uu.nl/haddock2.4/ (accessed 2025-02-11).

(21) mgl-admin. *AutoDock*. AutoDock. https://autodock.scripps.edu/ (accessed 2025-02-11).

(22) Henson, A. B.; Gromski, P. S.; Cronin, L. Designing Algorithms To Aid Discovery by Chemical Robots. *ACS Cent. Sci.***2018**, *4* (7), 793–804. https://doi.org/10.1021/acscentsci.8b00176.

(23) Verma, J.; Khedkar, V.; Coutinho, E. 3D-QSAR in Drug Design - A Review. *Curr. Top. Med. Chem.***2010**, *10* (1), 95–115. https://doi.org/10.2174/156802610790232260.

(24) Verma, R. P.; Hansch, C. Camptothecins: A SAR/QSAR Study. *Chem. Rev.***2009**, *109* (1), 213–235. https://doi.org/10.1021/cr0780210.

(25) Oliveira, T.; Silva, M.; Maia, E.; Silva, A.; Taranto, A. Virtual Screening Algorithms in Drug Discovery: A Review Focused on Machine and Deep Learning Methods. *Drugs Drug Candidates***2023**, *2* (2), 311–334. https://doi.org/10.3390/ddc2020017.

(26) Meng, X.-Y.; Zhang, H.-X.; Mezei, M.; Cui, M. Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery. *Curr. Comput. Aided-Drug Des.***2011**, *7* (2), 146–157. https://doi.org/10.2174/157340911795677602.

(27) Willett, P. Similarity-Based Virtual Screening Using 2D Fingerprints. *Drug Discov. Today***2006**, *11* (23–24), 1046–1053. https://doi.org/10.1016/j.drudis.2006.10.005.

(28) Surabhi, S.; Singh, B. K. COMPUTER AIDED DRUG DESIGN: AN OVERVIEW. *J. Drug Deliv. Ther.***2018**, *8* (5), 504–509. https://doi.org/10.22270/jddt.v8i5.1894.

(29) Tsalatsanis, A.; Yalcin, A.; Valavanis, Kimon. P. Dynamic Task Allocation in Cooperative Robot Teams. *Robotica***2012**, *30* (5), 721–730. https://doi.org/10.1017/S0263574711000920.

(30) Ghiandoni, G. M.; Bodkin, M. J.; Chen, B.; Hristozov, D.; Wallace, J. E. A.; Webster, J.; Gillet, V. J. Enhancing Reaction-Based de Novo Design Using a Multi-Label Reaction Class Recommender. *J. Comput. Aided Mol. Des.***2020**, *34* (7), 783–803. https://doi.org/10.1007/s10822-020-00300-6.

(31) *Frontiers in Chemistry*. https://www.frontiersin.org/journals/chemistry (accessed 2025-02-11).

(32) Agu, P. C.; Afiukwa, C. A.; Orji, O. U.; Ezeh, E. M.; Ofoke, I. H.; Ogbu, C. O.; Ugwuja, E. I.; Aja, P. M. Molecular Docking as a Tool for the Discovery of Molecular Targets of Nutraceuticals in Diseases Management. *Sci. Rep.***2023**, *13* (1), 13398. https://doi.org/10.1038/s41598-023-40160-2.

(33) *Software*. Rosetta Commons. https://rosettacommons.org/software/ (accessed 2025-02-11).

(34) Gani, R.; Zhang, L.; Kalakul, S.; Cignitti, S. Computer-Aided Molecular Design and Property Prediction. In *Computer Aided Chemical Engineering*; Elsevier, 2016; Vol. 39, pp 153–196. https://doi.org/10.1016/B978-0-444-63683-6.00006-X.

(35) Banegas-Luna, A.-J.; Cerón-Carrasco, J. P.; Pérez-Sánchez, H. A Review of Ligand-Based Virtual Screening Web Tools and Screening Algorithms in Large Molecular Databases in the Age of Big Data. *Future Med. Chem.***2018**, *10* (22), 2641–2658. https://doi.org/10.4155/fmc-2018-0076.

(36) Guner, O.; Clement, O.; Kurogi, Y. Pharmacophore Modeling and Three Dimensional Database Searching for Drug Design Using Catalyst: Recent Advances. *Curr. Med. Chem.***2004**, *11* (22), 2991–3005. https://doi.org/10.2174/0929867043364036.

(37) Marrone, T. J.; Briggs, And, J. M.; McCammon, J. A. STRUCTURE-BASED DRUG DESIGN:Computational Advances. *Annu. Rev. Pharmacol. Toxicol.***1997**, *37* (1), 71–90. https://doi.org/10.1146/annurev.pharmtox.37.1.71.

(38) Gane, P. J.; Dean, P. M. Recent Advances in Structure-Based Rational Drug Design. *Curr. Opin. Struct. Biol.***2000**, *10* (4), 401–404. https://doi.org/10.1016/S0959-440X(00)00105-6.

(39) Batool, M.; Ahmad, B.; Choi, S. A Structure-Based Drug Discovery Paradigm. *Int. J. Mol. Sci.***2019**, *20* (11), 2783. https://doi.org/10.3390/ijms20112783.

(40) Li, M.; Wang, Q.; Li, Y.; Cao, S.; Zhang, Y.; Wang, Z.; Liu, G.; Li, J.; Gu, B. Apical Sodium-Dependent Bile Acid Transporter, Drug Target for Bile Acid Related Diseases and Delivery Target for Prodrugs: Current and Future Challenges. *Pharmacol. Ther.***2020**, *212*, 107539. https://doi.org/10.1016/j.pharmthera.2020.107539.

(41) Zhong, S.; Macias, A.; MacKerell, A. Computational Identification of Inhibitors of Protein-Protein Interactions. *Curr. Top. Med. Chem.***2007**, *7* (1), 63–82. https://doi.org/10.2174/156802607779318334.

(42) Chen, F.; Hancock, C. N.; Macias, A. T.; Joh, J.; Still, K.; Zhong, S.; MacKerell, A. D.; Shapiro, P. Characterization of ATP-Independent ERK Inhibitors Identified through in Silico Analysis of the Active ERK2 Structure. *Bioorg. Med. Chem. Lett.***2006**, *16* (24), 6281–6287. https://doi.org/10.1016/j.bmcl.2006.09.038.

(43) Hafner, C.; Schmitz, G.; Meyer, S.; Bataille, F.; Hau, P.; Langmann, T.; Dietmaier, W.; Landthaler, M.; Vogt, T. Differential Gene Expression of Eph Receptors and Ephrins in Benign Human Tissues and Cancers. *Clin. Chem.***2004**, *50* (3), 490–499. https://doi.org/10.1373/clinchem.2003.026849.

(44) Dobrzanski, P.; Hunter, K.; Jones-Bolin, S.; Chang, H.; Robinson, C.; Pritchard, S.; Zhao, H.; Ruggeri, B. Antiangiogenic and Antitumor Efficacy of EphA2 Receptor

Antagonist. *Cancer Res.***2004**, *64* (3), 910–919. https://doi.org/10.1158/0008-5472.CAN-3430-2.

(45) Cheng, N.; Brantley, D.; Fang, W. B.; Liu, H.; Fanslow, W.; Cerretti, D. P.; Bussell, K. N.; Reith, A. D.; Jackson, D.; Chen, J. Inhibition of VEGF-Dependent Multistage Carcinogenesis by Soluble EphA Receptors. *Neoplasia***2003**, *5* (5), 445–456. https://doi.org/10.1016/S1476-5586(03)80047-7.

(46) Torres, G. E.; Gainetdinov, R. R.; Caron, M. G. Plasma Membrane Monoamine Transporters: Structure, Regulation and Function. *Nat. Rev. Neurosci.***2003**, *4* (1), 13–25. https://doi.org/10.1038/nrn1008.

(47) Mason, J.; Good, A.; Martin, E. 3-D Pharmacophores in Drug Discovery. *Curr. Pharm. Des.***2001**, *7* (7), 567–597. https://doi.org/10.2174/1381612013397843.

(48) González, P. M.; Acharya, C.; MacKerell, A. D.; Polli, J. E. Inhibition Requirements of the Human Apical Sodium-Dependent Bile Acid Transporter (hASBT) Using Aminopiperidine Conjugates of Glutamyl-Bile Acids. *Pharm. Res.***2009**, *26* (7), 1665–1678. https://doi.org/10.1007/s11095-009-9877-3.

(49) Bernard, D.; Coop, A.; MacKerell, A. D. Quantitative Conformationally Sampled Pharmacophore for δ Opioid Ligands: Reevaluation of Hydrophobic Moieties Essential for Biological Activity. *J. Med. Chem.***2007**, *50* (8), 1799–1809. https://doi.org/10.1021/jm0612463.

(50) Veselovsky, A.; Ivanov, A. Strategy of Computer-Aided Drug Design. *Curr. Drug Target -Infect. Disord.***2003**, *3* (1), 33–40. https://doi.org/10.2174/1568005033342145.

(51) Güner, O.; Clement, O.; Kurogi, Y. Pharmacophore Modeling and Three Dimensional Database Searching for Drug Design Using Catalyst: Recent Advances. *Curr. Med. Chem.***2004**, *11* (22), 2991–3005. https://doi.org/10.2174/0929867043364036.

(52) Koehn, F. E.; Carter, G. T. The Evolving Role of Natural Products in Drug Discovery. *Nat. Rev. Drug Discov.***2005**, *4* (3), 206–220. https://doi.org/10.1038/nrd1657.

(53) Lahlou, M. The Success of Natural Products in Drug Discovery. *Pharmacol. Amp Pharm.***2013**, *04* (03), 17–31. https://doi.org/10.4236/pp.2013.43A003.

(54) Lahlou, M. The Success of Natural Products in Drug Discovery. *Pharmacol. Amp Pharm.***2013**, *04* (03), 17–31. https://doi.org/10.4236/pp.2013.43A003.

(55) Marrone, T. J.; Briggs, And, J. M.; McCammon, J. A. STRUCTURE-BASED DRUG DESIGN:Computational Advances. *Annu. Rev. Pharmacol. Toxicol.***1997**, *37* (1), 71–90. https://doi.org/10.1146/annurev.pharmtox.37.1.71.

(56) Gane, P. J.; Dean, P. M. Recent Advances in Structure-Based Rational Drug Design. *Curr. Opin. Struct. Biol.***2000**, *10* (4), 401–404. https://doi.org/10.1016/S0959-440X(00)00105-6.

(57) Duchowicz, P. R.; Castro, E. A.; Fernández, F. M.; Gonzalez, M. P. A New Search Algorithm for QSPR/QSAR Theories: Normal Boiling Points of Some Organic Molecules. *Chem. Phys. Lett.***2005**, *412* (4–6), 376–380. https://doi.org/10.1016/j.cplett.2005.07.016.

(58) Wade, R. C.; Henrich, S.; Wang, T. Using 3D Protein Structures to Derive 3D-QSARs. *Drug Discov. Today Technol.***2004**, *1* (3), 241–246. https://doi.org/10.1016/j.ddtec.2004.11.018.

(59) Alam, S.; Khan, F. 3D-QSAR, Docking, ADME/Tox Studies on Flavone Analogs Reveal Anticancer Activity through Tankyrase Inhibition. *Sci. Rep.***2019**, *9* (1), 5414. https://doi.org/10.1038/s41598-019-41984-7.

(60) Cai, Z.; Zafferani, M.; Akande, O. M.; Hargrove, A. E. Quantitative Structure–Activity Relationship (QSAR) Study Predicts Small-Molecule Binding to RNA Structure. *J. Med. Chem.***2022**, *65* (10), 7262–7277. https://doi.org/10.1021/acs.jmedchem.2c00254.

(61) *BIOVIA Discovery Studio Visualizer | Dassault Systèmes*. https://www.3ds.com/products/biovia/discovery-studio/visualization (accessed 2025-02-16).

(62) Zhang, X.; Wang, J.; Song, Z.; Zhou, T. Data-Driven Ionic Liquid Design for CO_2 Capture: Molecular Structure Optimization and DFT Verification. *Ind. Eng. Chem. Res.***2021**, *60* (27), 9992–10000. https://doi.org/10.1021/acs.iecr.1c01384.

(63) Suay-Garcia, B.; Bueso-Bordils, J. I.; Falcó, A.; Pérez-Gracia, M. T.; Antón-Fos, G.; Alemán-López, P. Quantitative Structure–Activity Relationship Methods in the Discovery and Development of Antibacterials. *WIREs Comput. Mol. Sci.***2020**, *10* (6), e1472. https://doi.org/10.1002/wcms.1472.

(64) Topliss, J. G.; Edwards, R. P. Chance Factors in Studies of Quantitative Structure-Activity Relationships. *J. Med. Chem.***1979**, *22* (10), 1238–1244. https://doi.org/10.1021/jm00196a017.

(65) Cramer, R. D.; Patterson, D. E.; Bunce, J. D. Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding of Steroids to Carrier Proteins. *J. Am. Chem. Soc.***1988**, *110* (18), 5959–5967. https://doi.org/10.1021/ja00226a005.

(66) Akamatsu, M. Current State and Perspectives of 3D-QSAR. *Curr. Top. Med. Chem.***2002**, *2* (12), 1381–1394. https://doi.org/10.2174/1568026023392887.

(67) Abdullahi, M.; Uzairu, A.; Shallangwa, G. A.; Mamza, P. A.; Ibrahim, M. T. 2D-QSAR, 3D-QSAR, Molecular Docking and ADMET Prediction Studies of Some Novel 2-((1H-Indol-3-Yl)Thio)-N-Phenyl-Acetamide Derivatives as Anti-Influenza A Virus. *Egypt. J. Basic Appl. Sci.***2022**, *9* (1), 510–532. https://doi.org/10.1080/2314808X.2022.2108592.

(68) Ghose, A. K.; Viswanadhan, V. N.; Wendoloski, J. J. A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A Qualitative and Quantitative Characterization of Known Drug Databases. *J. Comb. Chem.***1999**, *1* (1), 55–68. https://doi.org/10.1021/cc9800071.

(69) Klebe, G.; Abraham, U.; Mietzner, T. Molecular Similarity Indices in a Comparative Analysis (CoMSIA) of Drug Molecules to Correlate and Predict Their Biological Activity. *J. Med. Chem.***1994**, *37* (24), 4130–4146. https://doi.org/10.1021/jm00050a010.

(70) Guillory, J. K. Handbook of Pharmaceutical Salts: Properties, Selection, and Use Edited by P. Heinrich Stahl and Camile G. Wermuth. VHCA, Verlag Helvetica Chimica Acta, Zürich, Switzerland, and Wiley-VCH, Weinheim, Germany. 2002. Vix + 374 Pp. 17.5 × 24.5 Cm. ISBN 3-906390-26-8. $130.00. *J. Med. Chem.***2003**, *46* (7), 1277–1277. https://doi.org/10.1021/jm030019n.

(71) Guan, P.; Doytchinova, I. A.; Flower, D. R. A Comparative Molecular Similarity Indices (CoMSIA) Study of Peptide Binding to the HLA-A3 Superfamily. *Bioorg. Med. Chem.***2003**, *11* (10), 2307–2311. https://doi.org/10.1016/S0968-0896(03)00109-3.

(72) Khedkar, S.; Malde, A.; Coutinho, E.; Srivastava, S. Pharmacophore Modeling in Drug Discovery and Development: An Overview. *Med. Chem.***2007**, *3* (2), 187–197. https://doi.org/10.2174/157340607780059521.

(73) Bernard, D.; Coop, A.; MacKerell, A. D. Conformationally Sampled Pharmacophore for Peptidic δ Opioid Ligands. *J. Med. Chem.***2005**, *48* (24), 7773–7780. https://doi.org/10.1021/jm050785p.

(74) Hajduk, P. J.; Greer, J. A Decade of Fragment-Based Drug Design: Strategic Advances and Lessons Learned. *Nat. Rev. Drug Discov.***2007**, *6* (3), 211–219. https://doi.org/10.1038/nrd2220.

(75) Fattori, D.; Squarcia, A.; Bartoli, S. Fragment-Based Approach to Drug Lead Discovery: Overview and Advances in Various Techniques. *Drugs RD***2008**, *9* (4), 217–227. https://doi.org/10.2165/00126839-200809040-00002.

(76) Zhang, W.; Huang, W.; Hu, J. Highly Stereoselective Synthesis of Monofluoroalkenes from α-Fluorosulfoximines and Nitrones. *Angew. Chem. Int. Ed.***2009**, *48* (52), 9858–9861. https://doi.org/10.1002/anie.200905077.

(77) Hajduk, P. J. Puzzling through Fragment-Based Drug Design. *Nat. Chem. Biol.***2006**, *2* (12), 658–659. https://doi.org/10.1038/nchembio1206-658.

(78) Pj, H. Fragment-Based Drug Design: How Big Is Too Big? *J. Med. Chem.***2006**, *49* (24). https://doi.org/10.1021/jm060511h.

(79) Jencks, W. P. On the Attribution and Additivity of Binding Energies. *Proc. Natl. Acad. Sci.***1981**, *78* (7), 4046–4050. https://doi.org/10.1073/pnas.78.7.4046.

(80) Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering High-Affinity Ligands for Proteins: SAR by NMR. *Science***1996**, *274* (5292), 1531–1534. https://doi.org/10.1126/science.274.5292.1531.

(81) Erlanson, D. A.; Wells, J. A.; Braisted, A. C. Tethering: Fragment-Based Drug Discovery. *Annu. Rev. Biophys. Biomol. Struct.***2004**, *33*, 199–223. https://doi.org/10.1146/annurev.biophys.33.110502.140409.

(82) Vanwetswinkel, S.; Heetebrij, R. J.; van Duynhoven, J.; Hollander, J. G.; Filippov, D. V.; Hajduk, P. J.; Siegal, G. TINS, Target Immobilized NMR Screening: An Efficient and Sensitive Method for Ligand Discovery. *Chem. Biol.***2005**, *12* (2), 207–216. https://doi.org/10.1016/j.chembiol.2004.12.004.

(83) Bosch, J.; Robien, M. A.; Mehlin, C.; Boni, E.; Riechers, A.; Buckner, F. S.; Van Voorhis, W. C.; Myler, P. J.; Worthey, E. A.; DeTitta, G.; Luft, J. R.; Lauricella, A.; Gulde, S.; Anderson, L. A.; Kalyuzhniy, O.; Neely, H. M.; Ross, J.; Earnest, T. N.; Soltis, M.; Schoenfeld, L.; Zucker, F.; Merritt, E. A.; Fan, E.; Verlinde, C. L. M. J.; Hol, W. G. J. Using Fragment Cocktail Crystallography to Assist Inhibitor Design of Trypanosoma Brucei Nucleoside 2-Deoxyribosyltransferase. *J. Med. Chem.***2006**, *49* (20), 5939–5946. https://doi.org/10.1021/jm060429m.

(84) Ciulli, A.; Williams, G.; Smith, A. G.; Blundell, T. L.; Abell, C. Probing Hot Spots at Protein-Ligand Binding Sites: A Fragment-Based Approach Using Biophysical Methods. *J. Med. Chem.***2006**, *49* (16), 4992–5000. https://doi.org/10.1021/jm060490r.

(85) *Chemical Biology: From Small Molecules to Systems Biology and Drug Design | Wiley*. Wiley.com. https://www.wiley.com/en-

us/Chemical+Biology%3A+From+Small+Molecules+to+Systems+Biology+and+Drug+Design-p-9783527619375 (accessed 2025-02-11).

(86) Bretonnet, A.-S.; Jochum, A.; Walker, O.; Krimm, I.; Goekjian, P.; Marcillat, O.; Lancelin, J.-M. NMR Screening Applied to the Fragment-Based Generation of Inhibitors of Creatine Kinase Exploiting a New Interaction Proximate to the ATP Binding Site. *J. Med. Chem.***2007**, *50* (8), 1865–1875. https://doi.org/10.1021/jm061460r.

(87) Chen, J.; Zhang, Z.; Stebbins, J. L.; Zhang, X.; Hoffman, R.; Moore, A.; Pellecchia, M. A Fragment-Based Approach for the Discovery of Isoform-Specific P38alpha Inhibitors. *ACS Chem. Biol.***2007**, *2* (5), 329–336. https://doi.org/10.1021/cb700025j.

(88) Chung, F.; Tisné, C.; Lecourt, T.; Dardel, F.; Micouin, L. NMR-Guided Fragment-Based Approach for the Design of tRNA(Lys3) Ligands. *Angew. Chem. Int. Ed Engl.***2007**, *46* (24), 4489–4491. https://doi.org/10.1002/anie.200605201.

(89) *PROTEINS: Structure, Function, and Bioinformatics | Protein Science Journal | Wiley Online Journal*. https://onlinelibrary.wiley.com/doi/abs/10.1002/prot.21334 (accessed 2025-02-11).

(90) Hajduk, P. J.; Greer, J. A Decade of Fragment-Based Drug Design: Strategic Advances and Lessons Learned. *Nat. Rev. Drug Discov.***2007**, *6* (3), 211–219. https://doi.org/10.1038/nrd2220.

(91) Linke, P.; Amaning, K.; Maschberger, M.; Vallee, F.; Steier, V.; Baaske, P.; Duhr, S.; Breitsprecher, D.; Rak, A. An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead Discovery. *J. Biomol. Screen.***2016**, *21* (4), 414–421. https://doi.org/10.1177/1087057115618347.

(92) Keserű, G. M.; Erlanson, D. A.; Ferenczy, G. G.; Hann, M. M.; Murray, C. W.; Pickett, S. D. Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia. *J. Med. Chem.***2016**, *59* (18), 8189–8206. https://doi.org/10.1021/acs.jmedchem.6b00197.

(93) Linke, P.; Amaning, K.; Maschberger, M.; Vallee, F.; Steier, V.; Baaske, P.; Duhr, S.; Breitsprecher, D.; Rak, A. An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead Discovery. *J. Biomol. Screen.***2016**, *21* (4), 414–421. https://doi.org/10.1177/1087057115618347.

(94) Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering High-Affinity Ligands for Proteins: SAR by NMR. *Science***1996**, *274* (5292), 1531–1534. https://doi.org/10.1126/science.274.5292.1531.

(95) Hajduk, P. J.; Dinges, J.; Schkeryantz, J. M.; Janowick, D.; Kaminski, M.; Tufano, M.; Augeri, D. J.; Petros, A.; Nienaber, V.; Zhong, P.; Hammond, R.; Coen, M.; Beutel, B.; Katz, L.; Fesik, S. W. Novel Inhibitors of Erm Methyltransferases from NMR and Parallel Synthesis. *J. Med. Chem.***1999**, *42* (19), 3852–3859. https://doi.org/10.1021/jm990293a.

(96) *Utility of NMR in lead optimization: fragment-based approaches - PubMed*. https://pubmed.ncbi.nlm.nih.gov/12470260/ (accessed 2025-02-11).

(97) Hofstadler, S. A.; Griffey, R. H. Analysis of Noncovalent Complexes of DNA and RNA by Mass Spectrometry. *Chem. Rev.***2001**, *101* (2), 377–390. https://doi.org/10.1021/cr990105o.

(98) Ee, S.; Ea, J.; Ka, S.-L.; Lb, B.; Lm, R.; S, A.; Sa, O.; Sa, H.; Rh, G. SAR by MS: A Ligand Based Technique for Drug Lead Discovery against Structured RNA Targets. *J. Med. Chem.***2002**, *45* (18). https://doi.org/10.1021/jm0255466.

(99) He, Y.; Yang, J.; Wu, B.; Robinson, D.; Sprankle, K.; Kung, P.-P.; Lowery, K.; Mohan, V.; Hofstadler, S.; Swayze, E. E.; Griffey, R. Synthesis and Evaluation of Novel Bacterial rRNA-Binding Benzimidazoles by Mass Spectrometry. *Bioorg. Med. Chem. Lett.***2004**, *14* (3), 695–699. https://doi.org/10.1016/j.bmcl.2003.11.031.

(100) *Astex, Structural Genomix, and Syrrx. I can see clearly now: structural biology and drug discovery - PubMed*. https://pubmed.ncbi.nlm.nih.gov/12618177/ (accessed 2025-02-11).

(101) Sharff, A.; Jhoti, H. High-Throughput Crystallography to Enhance Drug Discovery. *Curr. Opin. Chem. Biol.***2003**, *7* (3), 340–345. https://doi.org/10.1016/s1367-5931(03)00062-0.

(102) Mattos, C.; Ringe, D. Locating and Characterizing Binding Sites on Proteins. *Nat. Biotechnol.***1996**, *14* (5), 595–599. https://doi.org/10.1038/nbt0596-595.

(103) Yang, S.-Y. Pharmacophore Modeling and Applications in Drug Discovery: Challenges and Recent Advances. *Drug Discov. Today***2010**, *15* (11–12), 444–450. https://doi.org/10.1016/j.drudis.2010.03.013.

(104) *Chemical Computing Group (CCG) | Computer-Aided Molecular Design*. https://www.chemcomp.com/en/index.htm (accessed 2025-02-11).

(105) *Phase*. Schrödinger. https://www.schrodinger.com/platform/products/phase/ (accessed 2025-02-11).

(106) *products biovia discovery-studio visualization. - 3ds*. https://www.3ds.com/products/biovia/discovery-studio/visualization.?wockw=products%20OR%20biovia%20OR%20discovery%20studio%20OR%20visualization. (accessed 2025-02-11).

(107) *PharmMapper*. https://www.lilab-ecust.cn/pharmmapper/ (accessed 2025-02-11).

(108) *Open Babel*. SourceForge. https://sourceforge.net/projects/openbabel/ (accessed 2025-02-11).

(109) *Open Babel*. SourceForge. https://sourceforge.net/projects/openbabel/ (accessed 2025-02-11).

(110) Teague, S. J. Implications of Protein Flexibility for Drug Discovery. *Nat. Rev. Drug Discov.***2003**, *2* (7), 527–541. https://doi.org/10.1038/nrd1129.

(111) Jorgensen, W. L. Rusting of the Lock and Key Model for Protein-Ligand Binding. *Science***1991**, *254* (5034), 954–955. https://doi.org/10.1126/science.1719636.

(112) Liu, J.; He, X.; Zhang, J. Z. H. Improving the Scoring of Protein-Ligand Binding Affinity by Including the Effects of Structural Water and Electronic Polarization. *J. Chem. Inf. Model.***2013**, *53* (6), 1306–1314. https://doi.org/10.1021/ci400067c.

(113) Warren, G. L.; Andrews, C. W.; Capelli, A.-M.; Clarke, B.; LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S. A Critical Assessment of Docking Programs and Scoring Functions. *J. Med. Chem.***2006**, *49* (20), 5912–5931. https://doi.org/10.1021/jm050362n.

(114) Jorgensen, W. L. The Many Roles of Computation in Drug Discovery. *Science***2004**, *303* (5665), 1813–1818. https://doi.org/10.1126/science.1096361.

(115) Jorgensen, W. L. The Many Roles of Computation in Drug Discovery. *Science***2004**, *303* (5665), 1813–1818. https://doi.org/10.1126/science.1096361.

(116) *A Critical Assessment of Docking Programs and Scoring Functions | Journal of Medicinal Chemistry*. https://pubs.acs.org/doi/10.1021/jm050362n (accessed 2025-02-11).

(117) Walters, W. P.; Murcko, M. A. Prediction of 'Drug-Likeness.' *Adv. Drug Deliv. Rev.***2002**, *54* (3), 255–271. https://doi.org/10.1016/S0169-409X(02)00003-0.

(118) *Docking and scoring in virtual screening for drug discovery: methods and applications | Nature Reviews Drug Discovery*. https://www.nature.com/articles/nrd1549 (accessed 2025-02-11).

(119) Dror, R. O.; Dirks, R. M.; Grossman, J. P.; Xu, H.; Shaw, D. E. Biomolecular Simulation: A Computational Microscope for Molecular Biology. *Annu. Rev. Biophys.***2012**, *41*, 429–452. https://doi.org/10.1146/annurev-biophys-042910-155245.

(120) *Implications of protein flexibility for drug discovery | Nature Reviews Drug Discovery*. https://www.nature.com/articles/nrd1129 (accessed 2025-02-11).

(121) *Opportunities and obstacles for deep learning in biology and medicine | Journal of The Royal Society Interface*. https://royalsocietypublishing.org/doi/10.1098/rsif.2017.0387 (accessed 2025-02-11).

(122) *Docking and scoring in virtual screening for drug discovery: methods and applications | Nature Reviews Drug Discovery*. https://www.nature.com/articles/nrd1549 (accessed 2025-02-11).

(123) Williams, A. J.; Harland, L.; Groth, P.; Pettifer, S.; Chichester, C.; Willighagen, E. L.; Evelo, C. T.; Blomberg, N.; Ecker, G.; Goble, C.; Mons, B. Open PHACTS: Semantic Interoperability for Drug Discovery. *Drug Discov. Today***2012**, *17* (21–22), 1188–1198. https://doi.org/10.1016/j.drudis.2012.05.016.

(124) *Relative Binding Free Energy Calculations in Drug Discovery: Recent Advances and Practical Considerations | Journal of Chemical Information and Modeling*. https://pubs.acs.org/doi/10.1021/acs.jcim.7b00564 (accessed 2025-02-11).

(125) Gayathiri, E.; Prakash, P.; Kumaravel, P.; Jayaprakash, J.; Ragunathan, M. G.; Sankar, S.; Pandiaraj, S.; Thirumalaivasan, N.; Thiruvengadam, M.; Govindasamy, R. Computational Approaches for Modeling and Structural Design of Biological Systems: A Comprehensive Review. *Prog. Biophys. Mol. Biol.***2023**, *185*, 17–32. https://doi.org/10.1016/j.pbiomolbio.2023.08.002.

(126) *Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments | Journal of Computer-Aided Molecular Design*. https://link.springer.com/article/10.1007/s10822-013-9644-8 (accessed 2025-02-11).

(127) Meng, X.-Y.; Zhang, H.-X.; Mezei, M.; Cui, M. Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery. *Curr. Comput. Aided Drug Des.***2011**, *7* (2), 146–157. https://doi.org/10.2174/157340911795677602.

(128) *International Charter of principles for sharing bio-specimens and data | European Journal of Human Genetics*. https://www.nature.com/articles/ejhg2014197 (accessed 2025-02-11).

(129) Ryan, D. K.; Maclean, R. H.; Balston, A.; Scourfield, A.; Shah, A. D.; Ross, J. Artificial Intelligence and Machine Learning for Clinical Pharmacology. *Br. J. Clin. Pharmacol.***2024**, *90* (3), 629–639. https://doi.org/10.1111/bcp.15930.

(130) Collins, F. S.; Varmus, H. A New Initiative on Precision Medicine. *N. Engl. J. Med.***2015**, *372* (9), 793–795. https://doi.org/10.1056/NEJMp1500523.

(131) *Full article: A new wave of innovation in Semantic web tools for drug discovery*. https://www.tandfonline.com/doi/full/10.1080/17460441.2019.1586880 (accessed 2025-02-11).

(132) *Open science is a research accelerator | Nature Chemistry*. https://www.nature.com/articles/nchem.1149 (accessed 2025-02-11).

(133) Morgera, E.; Tsioumani, E.; Buck, M. *Unraveling The Nagoya Protocol: A Commentary of the Protocol on Access and Benefit-Sharing to the Convention on Biological Diversity*; Legal Studies on Access and Benefit-sharing; 2014; Vol. 2. https://doi.org/10.1163/9789004217188.

(134) Ranard, B. L.; Ha, Y. P.; Meisel, Z. F.; Asch, D. A.; Hill, S. S.; Becker, L. B.; Seymour, A. K.; Merchant, R. M. Crowdsourcing--Harnessing the Masses to Advance Health and Medicine, a Systematic Review. *J. Gen. Intern. Med.***2014**, *29* (1), 187–203. https://doi.org/10.1007/s11606-013-2536-8.

(135) Cao, Y.; Romero, J.; Olson, J. P.; Degroote, M.; Johnson, P. D.; Kieferová, M.; Kivlichan, I. D.; Menke, T.; Peropadre, B.; Sawaya, N. P. D.; Sim, S.; Veis, L.; Aspuru-Guzik, A. Quantum Chemistry in the Age of Quantum Computing. *Chem. Rev.***2019**, *119* (19), 10856–10915. https://doi.org/10.1021/acs.chemrev.8b00803.

(136) Hulsen, T. Literature Analysis of Artificial Intelligence in Biomedicine. *Ann. Transl. Med.***2022**, *10* (23), 1284. https://doi.org/10.21037/atm-2022-50.

(137) Hasin, Y.; Seldin, M.; Lusis, A. Multi-Omics Approaches to Disease. *Genome Biol.***2017**, *18* (1), 83. https://doi.org/10.1186/s13059-017-1215-1.

(138) *Green chemical analysis: main principles and current efforts towards greener analytical methodologies - Analytical Methods (RSC Publishing)*. https://pubs.rsc.org/en/content/articlelanding/2023/ay/d3ay01644g (accessed 2025-02-11).

(139) Rahwan, I.; Cebrian, M.; Obradovich, N.; Bongard, J.; Bonnefon, J.-F.; Breazeal, C.; Crandall, J. W.; Christakis, N. A.; Couzin, I. D.; Jackson, M. O.; Jennings, N. R.; Kamar, E.; Kloumann, I. M.; Larochelle, H.; Lazer, D.; McElreath, R.; Mislove, A.; Parkes, D. C.; Pentland, A. "Sandy"; Roberts, M. E.; Shariff, A.; Tenenbaum, J. B.; Wellman, M. Machine Behaviour. *Nature***2019**, *568* (7753), 477–486. https://doi.org/10.1038/s41586-019-1138-y.

(140) Beaudoin, M.; Kabanza, F.; Nault, V.; Valiquette, L. Evaluation of a Machine Learning Capability for a Clinical Decision Support System to Enhance Antimicrobial Stewardship Programs. *Artif. Intell. Med.***2016**, *68*, 29–36. https://doi.org/10.1016/j.artmed.2016.02.001.

(141) Silver, D.; Schrittwieser, J.; Simonyan, K.; Antonoglou, I.; Huang, A.; Guez, A.; Hubert, T.; Baker, L.; Lai, M.; Bolton, A.; Chen, Y.; Lillicrap, T.; Hui, F.; Sifre, L.; van den Driessche, G.; Graepel, T.; Hassabis, D. Mastering the Game of Go without Human Knowledge. *Nature***2017**, *550* (7676), 354–359. https://doi.org/10.1038/nature24270.

(142) Jumper, J.; Evans, R.; Pritzel, A.; Green, T.; Figurnov, M.; Ronneberger, O.; Tunyasuvunakool, K.; Bates, R.; Žídek, A.; Potapenko, A.; Bridgland, A.; Meyer, C.; Kohl, S. A. A.; Ballard, A. J.; Cowie, A.; Romera-Paredes, B.; Nikolov, S.; Jain, R.; Adler, J.; Back, T.; Petersen, S.; Reiman, D.; Clancy, E.; Zielinski, M.; Steinegger, M.; Pacholska, M.; Berghammer, T.; Bodenstein, S.; Silver, D.; Vinyals, O.; Senior, A. W.; Kavukcuoglu, K.; Kohli, P.; Hassabis, D. Highly Accurate Protein Structure Prediction with AlphaFold. *Nature***2021**, *596* (7873), 583–589. https://doi.org/10.1038/s41586-021-03819-2.

(143) *Advancing mathematics by guiding human intuition with AI | Nature*. https://www.nature.com/articles/s41586-021-04086-x (accessed 2025-02-11).

(144) Paszke, A.; Gross, S.; Massa, F.; Lerer, A.; Bradbury, J.; Chanan, G.; Killeen, T.; Lin, Z.; Gimelshein, N.; Antiga, L.; Desmaison, A.; Köpf, A.; Yang, E.; DeVito, Z.; Raison, M.; Tejani, A.; Chilamkurthy, S.; Steiner, B.; Fang, L.; Bai, J.; Chintala, S. PyTorch: An Imperative Style, High-Performance Deep Learning Library. arXiv December 3, 2019. https://doi.org/10.48550/arXiv.1912.01703.

(145) Sarwari, K. Using AI Tools for Teaching and Learning: A Systematic Review of Literature. *J. Cogn. Emot. Educ.***2024**, 1–14. https://doi.org/10.22034/cee.2024.491255.1031.

(146) Alanazi, A. A. A.; Fahad, A. I. A. A.; Almorshed, A. S. A.; Alrbian, A. A. M.; Alnughaymishi, A. A. S.; Al-Mutairi, N. H. B.; Alajmi, A. A.; Otaibi, S. G. A. Artificial Intelligence in Drug Discovery: Current Applications and Future Directions. *Int. J. Health Sci.***2022**, *6* (S10), 2011–2040. https://doi.org/10.53730/ijhs.v6nS10.15290.

(147) Stokes, J. M.; Yang, K.; Swanson, K.; Jin, W.; Cubillos-Ruiz, A.; Donghia, N. M.; MacNair, C. R.; French, S.; Carfrae, L. A.; Bloom-Ackermann, Z.; Tran, V. M.; Chiappino-Pepe, A.; Badran, A. H.; Andrews, I. W.; Chory, E. J.; Church, G. M.; Brown, E. D.; Jaakkola, T. S.; Barzilay, R.; Collins, J. J. A Deep Learning Approach to Antibiotic Discovery. *Cell***2020**, *180* (4), 688-702.e13. https://doi.org/10.1016/j.cell.2020.01.021.

(148) Fan, Y.-L.; Jin, X.-H.; Huang, Z.-P.; Yu, H.-F.; Zeng, Z.-G.; Gao, T.; Feng, L.-S. Recent Advances of Imidazole-Containing Derivatives as Anti-Tubercular Agents. *Eur. J. Med. Chem.***2018**, *150*, 347–365. https://doi.org/10.1016/j.ejmech.2018.03.016.

(149) Ghaderzadeh, M.; Shalchian, A.; Irajian, G.; Sadeghsalehi, H.; Zahedi bialvaei, A.; Sabet, B. Artificial Intelligence in Drug Discovery and Development Against Antimicrobial Resistance: A Narrative Review. *Iran. J. Med. Microbiol.***2024**, *18* (3), 135–147. https://doi.org/10.30699/ijmm.18.3.135.

(150) *Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery - PubMed*. https://pubmed.ncbi.nlm.nih.gov/33397265/ (accessed 2025-02-11).

(151) *Computational methods in drug discovery - PubMed*. https://pubmed.ncbi.nlm.nih.gov/24381236/ (accessed 2025-02-11).

(152) *Molecular Dynamics and Machine Learning for Reaction and Nanomaterial Design - ProQuest*. https://www.proquest.com/openview/f52acad84f65a9487894636334c7283a/1?pq-origsite=gscholar&cbl=18750&diss=y (accessed 2025-02-11).

(153) Fourches, D.; Barnes, J. C.; Day, N. C.; Bradley, P.; Reed, J. Z.; Tropsha, A. Cheminformatics Analysis of Assertions Mined from Literature That Describe Drug-Induced Liver Injury in Different Species. *Chem. Res. Toxicol.***2010**, *23* (1), 171–183. https://doi.org/10.1021/tx900326k.

(154) *(PDF) Artificial Intelligence in antidiabetic drug discovery: The advances in QSAR and the prediction of α-glucosidase inhibitors*. https://www.researchgate.net/publication/382221225_Artificial_Intelligence_in_antidiabetic_drug_discovery_The_advances_in_QSAR_and_the_prediction_of_a-glucosidase_inhibitors (accessed 2025-02-11).

(155) *Inverse molecular design using machine learning: Generative models for matter engineering | Science*. https://www.science.org/doi/10.1126/science.aat2663 (accessed 2025-02-12).

(156) Mahmood, H. Y.; Jamshidi, S.; Sutton, J. M.; Rahman, K. M. Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps. *Curr. Med. Chem.***2016**, *23* (10), 1062–1081. https://doi.org/10.2174/0929867323666160304150522.

(157) *Machine learning for microbial identification and antimicrobial susceptibility testing on MALDI-TOF mass spectra: a systematic review - PubMed*. https://pubmed.ncbi.nlm.nih.gov/32217160/ (accessed 2025-02-12).

(158) *Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps - PubMed*. https://pubmed.ncbi.nlm.nih.gov/26947776/ (accessed 2025-02-12).

(159) Weis, C. V.; Jutzeler, C. R.; Borgwardt, K. Machine Learning for Microbial Identification and Antimicrobial Susceptibility Testing on MALDI-TOF Mass Spectra: A Systematic Review. *Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis.***2020**, *26* (10), 1310–1317. https://doi.org/10.1016/j.cmi.2020.03.014.

(160) *A sparse Bayesian factor model for the construction of gene co-expression networks from single-cell RNA sequencing count data - PMC*. https://pmc.ncbi.nlm.nih.gov/articles/PMC7437941/ (accessed 2025-02-12).

(161) *Deep-Learning-Based Drug-Target Interaction Prediction - PubMed*. https://pubmed.ncbi.nlm.nih.gov/28264154/ (accessed 2025-02-12).

(162) *(PDF) How can quantum technologies be applied in healthcare, medicine, and the life sciences?* https://www.researchgate.net/publication/368372325_How_can_quantum_technologies_be_applied_in_healthcare_medicine_and_the_life_sciences (accessed 2025-02-12).

(163) *Quantum Computing for Healthcare: A Review*. https://www.mdpi.com/1999-5903/15/3/94 (accessed 2025-02-12).

(164) *A variational eigenvalue solver on a photonic quantum processor - PubMed*. https://pubmed.ncbi.nlm.nih.gov/25055053/ (accessed 2025-02-12).

(165) Singh, H.; Majumder, S.; Mishra, S. SHARC-VQE: Simplified Hamiltonian Approach with Refinement and Correction Enabled Variational Quantum Eigensolver for Molecular Simulation. arXiv July 17, 2024. https://doi.org/10.48550/arXiv.2407.12305.

(166) *Machine Learning in Healthcare Communication*. https://www.mdpi.com/2673-8392/1/1/21 (accessed 2025-02-12).

(167) *Drug–target interaction prediction by integrating heterogeneous information with mutual attention network*. http://ouci.dntb.gov.ua/en/works/4Vj0jbm4/ (accessed 2025-02-12).

(168) *Quantum Machine Learning in Prediction of Breast Cancer | Request PDF*. https://www.researchgate.net/publication/369636045_Quantum_Machine_Learning_in_Prediction_of_Breast_Cancer (accessed 2025-02-12).

(169) *"Nanohybrids" Based on pH-Responsive Hydrogels and Inorganic Nanoparticles for Drug Delivery and Sensor Applications | Nano Letters*. https://pubs.acs.org/doi/abs/10.1021/nl2011627 (accessed 2025-02-12).

(170) Wang, X. Quantum-Enhanced MRI Sensitivity: Dissolution-Dynamic Nuclear and Parahydrogen-Induced Polarization. *Highlights Sci. Eng. Technol.***2023**, *38*, 423–430. https://doi.org/10.54097/hset.v38i.5854.

(171) - *Abstract - Europe PMC*. https://europepmc.org/article/med/36776813 (accessed 2025-02-12).

(172) *Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data - PubMed*. https://pubmed.ncbi.nlm.nih.gov/27200455/ (accessed 2025-02-12).

(173) *Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline—a review - PMC*. https://pmc.ncbi.nlm.nih.gov/articles/PMC9358112/ (accessed 2025-02-12).

(174) Ghaderzadeh, M.; Shalchian, A.; Irajian, G.; Sadeghsalehi, H.; Zahedi bialvaei, A.; Sabet, B. Artificial Intelligence in Drug Discovery and Development Against Antimicrobial Resistance: A Narrative Review. *Iran. J. Med. Microbiol.***2024**, *18* (3), 135–147. https://doi.org/10.30699/ijmm.18.3.135.

(175) *Deep learning enables rapid identification of potent DDR1 kinase inhibitors | Request PDF*. https://www.researchgate.net/publication/335565604_Deep_learning_enables_rapid_identification_of_potent_DDR1_kinase_inhibitors (accessed 2025-02-12).

(176) *Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks | ACS Central Science*. https://pubs.acs.org/doi/10.1021/acscentsci.7b00512 (accessed 2025-02-12).

(177) Gómez-Bombarelli, R.; Wei, J. N.; Duvenaud, D.; Hernández-Lobato, J. M.; Sánchez-Lengeling, B.; Sheberla, D.; Aguilera-Iparraguirre, J.; Hirzel, T. D.; Adams, R. P.; Aspuru-Guzik, A. Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules. *ACS Cent. Sci.***2018**, *4* (2), 268–276. https://doi.org/10.1021/acscentsci.7b00572.

(178) (PDF) Deep Learning as an Opportunity in Virtual Screening. In *ResearchGate*.

(179) Wallach, I.; Dzamba, M.; Heifets, A. AtomNet: A Deep Convolutional Neural Network for Bioactivity Prediction in Structure-Based Drug Discovery. arXiv October 10, 2015. https://doi.org/10.48550/arXiv.1510.02855.

(180) Goh, G. B.; Hodas, N. O.; Vishnu, A. Deep Learning for Computational Chemistry. *J. Comput. Chem.***2017**, *38* (16), 1291–1307. https://doi.org/10.1002/jcc.24764.

(181) Liao, Z.; You, R.; Huang, X.; Yao, X.; Huang, T.; Zhu, S. DeepDock: 2019 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). *2019 IEEE Int.*

*Conf. Bioinforma. Biomed. BIBM***2020**, 311–317. https://doi.org/10.1109/bibm47256.2019.8983365.

(182) Wen, M.; Zhang, Z.; Niu, S.; Sha, H.; Yang, R.; Yun, Y.; Lu, H. Deep-Learning-Based Drug-Target Interaction Prediction. *J. Proteome Res.***2017**, *16* (4), 1401–1409. https://doi.org/10.1021/acs.jproteome.6b00618.

(183) Ghaderzadeh, M.; Shalchian, A.; Irajian, G.; Sadeghsalehi, H.; Zahedi bialvaei, A.; Sabet, B. Artificial Intelligence in Drug Discovery and Development Against Antimicrobial Resistance: A Narrative Review. *Iran. J. Med. Microbiol.***2024**, *18* (3), 135–147. https://doi.org/10.30699/ijmm.18.3.135.

(184) Mahmood, H. Y.; Jamshidi, S.; Sutton, J. M.; Rahman, K. M. Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps. *Curr. Med. Chem.***2016**, *23* (10), 1062–1081. https://doi.org/10.2174/0929867323666160304150522.

(185) *(PDF) How can quantum technologies be applied in healthcare, medicine, and the life sciences?* https://www.researchgate.net/publication/368372325_How_can_quantum_technologies_be_applied_in_healthcare_medicine_and_the_life_sciences (accessed 2025-02-12).

(186) *Quantum Computing in Medicine*. http://ouci.dntb.gov.ua/en/works/9jLoyKO4/ (accessed 2025-02-12).

(187) *A variational eigenvalue solver on a photonic quantum processor - PubMed*. https://pubmed.ncbi.nlm.nih.gov/25055053/ (accessed 2025-02-12).

(188) Singh, H.; Majumder, S.; Mishra, S. SHARC-VQE: Simplified Hamiltonian Approach with Refinement and Correction Enabled Variational Quantum Eigensolver for Molecular Simulation. arXiv July 17, 2024. https://doi.org/10.48550/arXiv.2407.12305.

(189) *Significance of machine learning in healthcare: Features, pillars and applications-SciEngine*. https://www.sciengine.com/TJIN/doi/10.1016/j.ijin.2022.05.002 (accessed 2025-02-12).

(190) *Quantum Machine Learning in Prediction of Breast Cancer | Request PDF*. https://www.researchgate.net/publication/369636045_Quantum_Machine_Learning_in_Prediction_of_Breast_Cancer (accessed 2025-02-12).

(191) Rümenapp, C.; Gleich, B.; Haase, A. Magnetic Nanoparticles in Magnetic Resonance Imaging and Diagnostics. *Pharm. Res.***2012**, *29* (5), 1165–1179. https://doi.org/10.1007/s11095-012-0711-y.

(192) Wang, X. Quantum-Enhanced MRI Sensitivity: Dissolution-Dynamic Nuclear and Parahydrogen-Induced Polarization. *Highlights Sci. Eng. Technol.***2023**, *38*, 423–430. https://doi.org/10.54097/hset.v38i.5854.

(193) *Quantum sensors for biomedical applications - PubMed*. https://pubmed.ncbi.nlm.nih.gov/36776813/ (accessed 2025-02-12).

(194) *Quantum healthcare computing using precision based granular approach | Semantic Scholar*. https://www.semanticscholar.org/paper/Quantum-healthcare-computing-using-precision-based-Aggarwal-Sachdeva/ea9944be90f902e3ffb2d8923475586e8559ce17 (accessed 2025-02-12).

(195) *Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review - PubMed*. https://pubmed.ncbi.nlm.nih.gov/34303871/ (accessed 2025-02-12).

(196) *Computer Aided Drug Design: Success and Limitations - PubMed*. https://pubmed.ncbi.nlm.nih.gov/26601966/ (accessed 2025-02-12).

(197) Ejalonibu, M. A.; Ogundare, S. A.; Elrashedy, A. A.; Ejalonibu, M. A.; Lawal, M. M.; Mhlongo, N. N.; Kumalo, H. M. Drug Discovery for Mycobacterium Tuberculosis Using Structure-Based Computer-Aided Drug Design Approach. *Int. J. Mol. Sci.***2021**, *22* (24), 13259. https://doi.org/10.3390/ijms222413259.

(198) Sabet, M.; Tarazi, Z.; Nolan, T.; Parkinson, J.; Rubio-Aparicio, D.; Lomovskaya, O.; Dudley, M. N.; Griffith, D. C. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae. *Antimicrob. Agents Chemother.***2018**, *62* (1), e01446-17. https://doi.org/10.1128/AAC.01446-17.

(199) (PDF) A REVIEW ON COMPUTER AIDED DRUG DESIGN IN DRUG DISCOVERY. *ResearchGate***2024**. https://doi.org/10.20959/wjpps20177-9450.

(200) *Computer-aided drug design in anti-cancer drug discovery: What have we learnt and what is the way forward? - ScienceDirect*. https://www.sciencedirect.com/science/article/pii/S2352914823001788 (accessed 2025-02-12).

(201) *PubChem Substance and Compound databases - PubMed*. https://pubmed.ncbi.nlm.nih.gov/26400175/ (accessed 2025-02-12).

(202) *Featured Publications | Fraternal Order of Eagles Diabetes Research Center - Carver College of Medicine | The University of Iowa*. https://diabetes.medicine.uiowa.edu/research/featured-publications (accessed 2025-02-12).

(203) Aggarwal, L.; Sachdeva, S.; Goswami, P. Quantum Healthcare Computing Using Precision Based Granular Approach. *Appl. Soft Comput.***2023**, *144*, 110458. https://doi.org/10.1016/j.asoc.2023.110458.

(204) *Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review - PubMed*. https://pubmed.ncbi.nlm.nih.gov/34303871/ (accessed 2025-02-12).

(205) Baig, M. H.; Ahmad, K.; Roy, S.; Ashraf, J. M.; Adil, M.; Siddiqui, M. H.; Khan, S.; Kamal, M. A.; Provazník, I.; Choi, I. Computer Aided Drug Design: Success and Limitations. *Curr. Pharm. Des.***2016**, *22* (5), 572–581. https://doi.org/10.2174/1381612822666151125000550.

(206) Ejalonibu, M. A.; Ogundare, S. A.; Elrashedy, A. A.; Ejalonibu, M. A.; Lawal, M. M.; Mhlongo, N. N.; Kumalo, H. M. Drug Discovery for Mycobacterium Tuberculosis Using Structure-Based Computer-Aided Drug Design Approach. *Int. J. Mol. Sci.***2021**, *22* (24), 13259. https://doi.org/10.3390/ijms222413259.

(207) Sabet, M.; Tarazi, Z.; Nolan, T.; Parkinson, J.; Rubio-Aparicio, D.; Lomovskaya, O.; Dudley, M. N.; Griffith, D. C. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae. *Antimicrob. Agents Chemother.***2018**, *62* (1), e01446-17. https://doi.org/10.1128/AAC.01446-17.

(208) A, C.; A, B.; Mekkanti, M. R.; Rinku, M. A REVIEW ON COMPUTER AIDED DRUG DESIGN (CAAD) AND IT'S IMPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT PROCESS. *Int. J. Health Care Biol. Sci.***2020**, 27–33.

(209) *Computer-aided drug design in anti-cancer drug discovery: What have we learnt and what is the way forward? ? | Semantic Scholar*. https://www.semanticscholar.org/paper/Computer-aided-drug-design-in-anti-cancer-drug-What-Opeyemi-Paul/560f6fac91fd197bfabfafba619b81c541fb070c (accessed 2025-02-12).

(210) Barabási, A.-L.; Gulbahce, N.; Loscalzo, J. Network Medicine: A Network-Based Approach to Human Disease. *Nat. Rev. Genet.***2011**, *12* (1), 56–68. https://doi.org/10.1038/nrg2918.

(211) *Network-based strategies can help mono- and poly-pharmacology drug discovery: a systems biology view - PubMed*. https://pubmed.ncbi.nlm.nih.gov/23713773/ (accessed 2025-02-12).

(212) Wang, X.; Wei, X.; Thijssen, B.; Das, J.; Lipkin, S. M.; Yu, H. Three-Dimensional Reconstruction of Protein Networks Provides Insight into Human Genetic Disease. *Nat. Biotechnol.***2012**, *30* (2), 159–164. https://doi.org/10.1038/nbt.2106.

(213) Buchan, N. S.; Rajpal, D. K.; Webster, Y.; Alatorre, C.; Gudivada, R. C.; Zheng, C.; Sanseau, P.; Koehler, J. The Role of Translational Bioinformatics in Drug Discovery. *Drug Discov. Today***2011**, *16* (9–10), 426–434. https://doi.org/10.1016/j.drudis.2011.03.002.

(214) *Proteomics reveals that proteins expressed during the early stage of Bacillus anthracis infection are potential targets for the development of vaccines and drugs - PubMed*. https://pubmed.ncbi.nlm.nih.gov/15862115/ (accessed 2025-02-12).

(215) García-Lara, J.; Masalha, M.; Foster, S. J. Staphylococcus Aureus: The Search for Novel Targets. *Drug Discov. Today***2005**, *10* (9), 643–651. https://doi.org/10.1016/S1359-6446(05)03432-X.

(216) *Identification of novel steroid target genes through the combination of bioinformatics and functional analysis of hormone response elements - PubMed*. https://pubmed.ncbi.nlm.nih.gov/16289377/ (accessed 2025-02-12).

(217) Li, H.; Gao, Z.; Kang, L.; Zhang, H.; Yang, K.; Yu, K.; Luo, X.; Zhu, W.; Chen, K.; Shen, J.; Wang, X.; Jiang, H. TarFisDock: A Web Server for Identifying Drug Targets with Docking Approach. *Nucleic Acids Res.***2006**, *34* (Web Server issue), W219-224. https://doi.org/10.1093/nar/gkl114.

(218) *Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach - PubMed*. https://pubmed.ncbi.nlm.nih.gov/11766046/ (accessed 2025-02-12).